^
5d
PCP4/PEP19 and HER2 Are Novel Prognostic Markers in Mucoepidermoid Carcinoma of the Salivary Gland. (PubMed, Cancers (Basel))
Patients that were PCP4/PEP19-positive and HER2-negative showed similar outcomes to PCP4/PEP19 and HER2 alone. Therefore, PCP4/PEP19 and HER2 are predicted to play important roles in the pathogenesis and progression of MEC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • HER-2 expression
5d
Potential biomarkers and signaling pathways associated with the pathogenesis of primary salivary gland carcinoma: a bioinformatics study. (PubMed, Genomics Inform)
SPIB, FOXM1, and POLR2A significantly regulate all the hub genes. This study illustrated several hub genes and their master regulators that might be appropriate targets for the therapeutic aims of primary SGC.
Journal
|
TP53 (Tumor protein P53) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • NOTCH1 (Notch 1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • SPP1 (Secreted Phosphoprotein 1) • EGF (Epidermal growth factor) • COL1A1 (Collagen, type I, alpha 1) • FOXM1 (Forkhead Box M1) • CCNB1 (Cyclin B1)
5d
Clinical • Trial completion • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
Opdivo (nivolumab)
6d
Prognostic Significance of Cancer Stem Cell Markers in Patients With Salivary Gland Carcinomas. (PubMed, Appl Immunohistochem Mol Morphol)
Besides the significant association between low SOX2 expression and higher grades of MEC, we found no statistically significant correlation between the studied CSC markers and patients' survival or clinicopathologic features. Therefore, a larger sample size with long-term follow-up is beneficial for thorough investigations toward the main role of CSCs in patients with SGCs.
Clinical • Journal
|
CD133 • CD44 • SOX2
|
CD44 expression • CD133 expression
9d
Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report. (PubMed, BMC Med Genomics)
High-grade transformed SC showed aggressive clinical and pathological features with increased Ki-67 labeling index. Molecular genetic study of gene rearrangement appears to be beneficial treatment as the presence of ETV6-NTRK3 translocation may represent a therapeutic target in SC, particularly the high-grade transformed type.
Clinical • Journal
|
TP53 (Tumor protein P53) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
|
NTRK3 fusion • ETV6-NTRK3 fusion
|
Rozlytrek (entrectinib)
11d
Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology. (PubMed, Head Neck Pathol)
Because RET and ALK fusions are targetable, it is important to recognize the broad spectrum of frankly invasive carcinomas that can arise from IDC, particularly because some cases are completely overrun or recur without any recognizable IDC component. These results suggest fusion analysis may be of clinical benefit on any salivary gland (adeno) carcinoma, not otherwise specified or salivary duct carcinoma.
Journal
|
ALK (Anaplastic lymphoma kinase) • AR (Androgen receptor) • STRN (Striatin) • NCOA4 (Nuclear Receptor Coactivator 4) • TRIM33 (Tripartite Motif Containing 33) • SOX10 (SRY-Box 10) • TRIM3 (Tripartite Motif Containing 3) • TP63 (Tumor protein 63)
|
ALK fusion
12d
EMT in salivary gland tumors: the expression of microRNAs miR-155 and miR-200c is associated with clinical-pathological parameters. (PubMed, Mol Biol Rep)
This study provides evidence of alterations in the expression of EMT-factors regulating miRs, especially of miR-9, miR-138, miR-155, and miR-200c. No significant relationships were found between the expression of these miRs and proteins associated with EMT in SGTs.
Clinical • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • MIR155 (MicroRNA 155) • MIR34A (MicroRNA 34a-5p) • MIR200C (MicroRNA 200c) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • MIR138 (MicroRNA 138)
|
KIT expression • CDH1 expression • miR-155 expression • ZEB1 expression
12d
Salivary gland papillary adenocarcinoma with intestinal-like features: Clinicopathologic, immunohistochemical, and genetic study of six cases. (PubMed, J Oral Pathol Med)
We describe 6 cases of salivary gland papillary adenocarcinoma with intestinal-like mucinous cytologic features, which are different from conventional intestinal-type adenocarcinoma, presenting a consistent immunophenotype of CK7 & MUC1 positive, CK20 & CDX-2 negative and exhibiting recurrent AKT1 E17K mutations.
Clinical • Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1) • MUC1 (Mucin 1) • SOX10 (SRY-Box 10) • CDX-2 • MUC2 • MUC5AC (Mucin 5AC)
|
AKT1 E17K • AKT1 mutation
13d
Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma (clinicaltrials.gov)
P2, N=41, Active, not recruiting, Samsung Medical Center | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2021 --> Sep 2022
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Herzuma (trastuzumab biosimilar)
17d
ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing. (PubMed, Mod Pathol)
Approximately 30% SDC harbor HER2 amplification and response to trastuzumab has been reported...FC and TCN were binarized with respective cutoffs of ≥1.8 and ≥6.0 and the proportion of agreement with FISH were 95% and 92%, respectively. The assessment of ERBB2 copy number by NGS is accurate and reliable with FC or TCN nearly equivalent to FISH in identifying HER2 amplified SDC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 overexpression
|
Herceptin (trastuzumab)
20d
Mammary analogue secretory carcinoma: A challenging case arising in a young man with radiation exposure. (PubMed, Ann Diagn Pathol)
The cytologic features of MASC are not entirely distinctive and can simulate acinic cell carcinoma, but the tumor harbors an ETV6 gene rearrangement resulting in an ETV6-NTRK3 fusion gene. We present a case of MASC arising in a 31 year old man with a history of multiple radio-embolization procedures.
Clinical • Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK3 fusion • ETV6-NTRK3 fusion
20d
Cytopathological Findings of Secretory Carcinoma of the Salivary Gland and the Diagnostic Utility of Giemsa Staining. (PubMed, Diagnostics (Basel))
Giemsa staining revealed cytoplasmic vacuolation, intracytoplasmic metachromatic secretions and/or various sized metachromatic granules, and a background of metachromatic mucin in all four specimens. Given this, we conclude that these cytological findings, especially those of the Giemsa staining, might be helpful in the diagnosis of secretory carcinoma.
Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK3 fusion • ETV6-NTRK3 fusion
24d
A mechanistic basis for the malignant progression of salivary gland tumors. (PubMed, iScience)
Lineage tracing experiments showed that SLG tumor cells undergo an extensive epithelial-mesenchymal transition (EMT) and TGF-β-responding tumor cells are a source of mesenchymal tumor cells invading the surrounding stroma. This study advances our understanding of the mechanistic basis of salivary gland malignancy and may help combat this highly heterogeneous cancer.
Journal
|
HRAS (Harvey rat sarcoma viral oncogene homolog) • SOX2 • TGFB1 (Transforming Growth Factor Beta 1) • HMGA2 (High mobility group AT-hook 2)
24d
Diagnosis and treatment of secretory carcinoma arising from the oral minor salivary gland: Two case reports. (PubMed, Medicine (Baltimore))
It is highly likely for many cases of SC to be initially diagnosed as acinic cell carcinoma (AciCC) owing to their similar histological findings. The treatment strategy for minor salivary gland-originated SC is similar to that of AciCC; however, SC is often highly malignant and involves a high risk of cervical lymph node metastasis. Thus, establishing an accurate diagnosis together with pathologists and confirming the presence of the ETS variant 6-neurotrophic receptor tyrosine kinase 3 fusion gene using genetic analysis is important.
Clinical • Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase)
24d
Lysosomal and cytoskeletal events in epithelial salivary tumours as assessed by imunohistochemistry for CD63 and HSP27. (PubMed, Pathol Res Pract)
Expression of CD63 is preferentially associated with differentiated or simple luminal cell phenotypes in epithelial salivary tumours and possibly reflects autophagy of secretory granules or absorption of luminal material. Expression of HSP27 is preferentially associated with non-luminal cells and possibly reflects remodelling of the cytoskeleton.
Journal
|
HSPB1 (Heat shock 27kDa protein 1)
|
HSPB1 expression
26d
Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer. (PubMed, Eur J Cancer)
This study showed too many severe cabozantinib-associated wound complications in patients with SGC, especially in prior irradiated areas. Therefore, the study closed prematurely. The efficacy in the limited number of evaluable patients was low to moderate.
Clinical • P2 data • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET positive
|
Cabometyx (cabozantinib tablet)
27d
Aspiration cytology of pleomorphic adenoma with squamous metaplasia: A case series and literature review illustrating diagnostic challenges. (PubMed, Diagn Cytopathol)
Squamous metaplasia in PAs is not associated with adverse outcomes, but may induce reactive changes upon aspiration/irritation, resulting in worrisome cytologic features. PLAG1 IHC is a useful adjunct when characteristic cytologic features for PAs are absent or obscured. Prudent use of the diagnostic category salivary gland neoplasm of uncertain malignant potential (SUMP) in the Milan system can avoid overtreatment.
Clinical • Review • Journal
|
PLAG1 (PLAG1 Zinc Finger)
1m
Integrative analysis of long non-coding RNAs and mRNAs associated with tumorigenesis of salivary gland pleomorphic adenoma. (PubMed, Arch Oral Biol)
These data suggested that the differently expressed lncRNAs may contribute to the tumorigenesis of SGPA, and analyzing the differences in the lncRNA expression profiles may provide novel insights into the pathogenesis of SGPA.
Journal
|
TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • IGF2 (Insulin-like growth factor 2) • PLAG1 (PLAG1 Zinc Finger) • MIR195 (MicroRNA 195)
1m
NUT Carcinoma of the Submandibular Gland: A Case at This Uncommon Site with Review of the Literature. (PubMed, Head Neck Pathol)
Salivary gland is an unusual site for NUT carcinoma and is rarely described in submandibular gland. We reviewed the clinicopathologic features of this entity at this site along with role of NUTM1 gene rearrangements in NUT tumorigenesis.
Clinical • Review • Journal
|
BRD4 (Bromodomain Containing 4) • NUTM1 (NUT Midline Carcinoma Family Member 1)
1m
A Case Report of Mucoepidermoid Carcinoma With Extensive Keratinization in Parotid: Expanding the Morphologic Spectrum. (PubMed, Int J Surg Pathol)
MAML2 gene break-apart and CRTC1-MAML2 gene fusion were detected by fluorescence in situ hybridization. This is the first report to describe a MEC case with extensive squamous metaplasia and overt keratin pearls formation, which expands the morphologic spectrum of MEC.
Clinical • Journal
|
CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
1m
Discovery proteomics reveals potential protein signature associated with malignant phenotype acquisition in pleomorphic adenoma. (PubMed, Oral Dis)
In this work, we demonstrated the comparative proteomic profiling of PA, residual PA, and CXPA, and seven were proposed as protein signatures, some of which may be associated with the malignant phenotype acquisition.
Journal
|
APOA1 (Apolipoprotein A-I)
1m
NR4A3 (Nuclear receptor subfamily 4 group A member 3) • SOX10 (SRY-Box 10)
1m
CDKN2A (Cyclin-dependent kinase inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
1m
Analysis of clinicopathologic features and expression of NR4A3 in sinonasal acinic cell carcinoma. (PubMed, Mod Pathol)
Our study demonstrated that sinonasal AiCCs are characterized by an indolent nature and histopathological similarity to parotid AiCCs. Moreover, NR4A3 is a reliable biomarker for distinguishing sinonasal AiCCs from other sinonasal carcinomas.
Clinical • Journal
|
NR4A3 (Nuclear receptor subfamily 4 group A member 3) • CA9 (Carbonic anhydrase 9) • TP63 (Tumor protein 63)
1m
VUBAR: Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients (clinicaltrials.gov)
P2, N=55, Recruiting, Universitair Ziekenhuis Brussel | N=20 --> 55 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Nov 2022 --> Nov 2024
Clinical • Enrollment change • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2-H
1m
Metatypical Adenoid Cystic Carcinoma: A Variant Showing Prominent Squamous Differentiation With a Predilection for the Sinonasal Tract and Skull Base. (PubMed, Am J Surg Pathol)
Recently, we have come across 3 cases of adenoid cystic carcinomas involving the sinonasal tract and skull base having extensive interconnecting trabecular growth, macrocysts, and squamous differentiation, yet demonstrating the signature fusions involving MYB-NFIB and MYBL1-NFIB by RNA sequencing. In this article, we describe the clinical, histomorphologic, and imaging findings of these cases and propose the appellation "metatypical adenoid cystic carcinoma" for this uncommon variant morphology.
Journal
|
NFIB (Nuclear Factor I B)
1m
Squamoglandular Variant of Acinic Cell Carcinoma: A Case Report of a Novel Variant. (PubMed, Head Neck Pathol)
Based on these findings, this tumor is best considered a "squamoglandular variant of acinic cell carcinoma." Morphologic and clinical evidence argues against this representing a form of high-grade transformation. While overall bland, the differential diagnosis may include various basaloid tumors in the parotid gland, both primary and metastatic.
Clinical • Journal
|
NR4A3 (Nuclear receptor subfamily 4 group A member 3) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
2ms
Breast Cancer Metastasis to the Parotid: A Case Report with Imaging Findings. (PubMed, Am J Case Rep)
She had a past history of left breast cancer 6 years ago, treated by left modified radical mastectomy with axillary lymph node dissection followed by adjuvant chemotherapy, radiation therapy, and trastuzumab...CONCLUSIONS We report a rare case of metastasis from breast cancer to the parotid gland, with imaging findings including neck ultrasonography and contrast-enhanced neck computed tomography. Breast cancer rarely metastasizes to the parotid gland, but radiologists should be aware of this possibility, especially in patients with a prior history of breast cancer.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
HER-2 negative • HER-2 expression • ER expression
|
Herceptin (trastuzumab)
2ms
Clinicopathological characteristics and outcomes of 23 patients with secretory carcinoma of major salivary glands. (PubMed, Sci Rep)
SCSGs are typically indolent, with a low locoregional recurrence rate and excellent survival. Prognosis is correlated to clinical stage, pathological grade, and surgical procedures.
Clinical • Journal
|
ETV6 (ETS Variant Transcription Factor 6) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
2ms
Intrasalivary Thymic Carcinoma: A Case Report and Literature Review. (PubMed, Head Neck Pathol)
We postulate that similar cases should be designated as intrasalivary thymic carcinoma analogically to similar thyroid tumors. Our case and the limited literature data indicate they should be distinguished from conventional squamous cell carcinoma of major salivary glands due to their rather favorable prognosis.
Clinical • Review • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD5 (CD5 Molecule) • TP63 (Tumor protein 63)
|
CD5 positive
2ms
[VIRTUAL] Comparison of Fusion Detection Methods in Salivary Gland Tumors (AMP 2021)
There was relatively high discordance between FISH and targeted RNA sequencing results. Thus, if fusion analysis results are conflicting with the morphologic impression, a second mode of fusion detection may be warranted. Although both methods have advantages and drawbacks, RNA sequencing provides additional information about novel fusion partners, as well as fusions that may not have been originally considered.
FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • PLAG1 (PLAG1 Zinc Finger) • MAML2 (Mastermind Like Transcriptional Coactivator 2) • HMGA2 (High mobility group AT-hook 2)
2ms
Undifferentiated and dedifferentiated head and neck carcinomas. (PubMed, Semin Diagn Pathol)
Overall, these tumors often represent a diagnostic challenge, especially in small biopsies. This review summarizes and discuss the diagnostic approach to the main head and neck carcinoma types that frequently or occasionally display an undifferentiated appearance, with a focus on salivary gland, oropharyngeal, nasopharyngeal and sinonasal subsites.
Review • Journal
|
NUTM1 (NUT Midline Carcinoma Family Member 1)
2ms
Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma. (PubMed, Pathol Res Pract)
Clinicopathological features of sarcomatoid SDCs were not different from typical SDC, and genomic alteration according to subtypes was also similar to that of the conventional type. Androgen receptor (AR) expression is helpful in the diagnosis of SDC. The findings indicate that EMA and AR are useful in diagnosing sarcomatoid SDC when the tumor is composed of predominantly sarcomatoid components.
Journal
|
TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • AR (Androgen receptor)
|
AR expression
2ms
iPRIME: Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors (clinicaltrials.gov)
P2, N=46, Recruiting, University of Chicago | Trial primary completion date: Sep 2021 --> Sep 2022
Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • docetaxel
2ms
Expanding the clinicopathological spectrum of TGFBR3-PLAG1 rearranged salivary gland neoplasms with myoepithelial differentiation including evidence of high-grade transformation. (PubMed, Genes Chromosomes Cancer)
However, evidence of minimal invasion advocates classification as low-grade myoepithelial carcinoma. This case series further characterizes the spectrum of uncommon cellular myoepithelial neoplasms harboring TGFBR3-PLAG1 fusion, which show recurrent minimal invasion of the adjacent salivary gland tissue, a predilection to the deep lobe of the parotid gland and potential high-grade transformation.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PLAG1 (PLAG1 Zinc Finger)
|
TP53 mutation • HER-2 amplification • HER-2 mutation
2ms
Low Mutational Burden of Extra Nodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome (ASH 2021)
The low mutational load and lack of a clear lymphoma related gene signature suggests that localized pSS MALT lymphomas are genetically stable and most likely depend on the inflammatory state of the micro-environment. Only those cases characterized by higher mutational load showed a relapse-remitting disease, as is typical for indolent lymphoma. These observations could be translated to the clinical setting and potentially have value as biomarker for identification of patients with a more aggressive disease.
Clinical • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden) • PAX5 (Paired Box 5) • MALT1 (MALT1 Paracaspase) • MUC4 (Mucin 4, Cell Surface Associated) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5) • PRKD1 (Protein Kinase D1)
|
TMB-L
3ms
DART: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
P2, N=818, Recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2022 --> Oct 2023 | Trial primary completion date: Aug 2022 --> Oct 2023
Clinical • Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
PD-L1 overexpression • PD-L1 amplification
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
3ms
[VIRTUAL] Identification of Salivary Gland Tumors (SGT) at Risk for Local or Distant Recurrence After Postoperative Radiation Therapy (PORT) With or Without Systemic Therapy (ST) Using Clinical Risk Grouping (ASTRO 2021)
Regimens included carboplatin + paclitaxel, cisplatin, and concurrent/adjuvant trastuzumab (in 10 pts with HER2-positive SGT). DM are the primary mode of recurrence in pts with resected SGT treated with PORT +/- ST and occurred only in high-risk pts. After randomized trials like RTOG 1008 determine the added benefit of chemo to PORT, DM is likely to remain an unmet need. Further studies incorporating molecular characterization of high-grade SGT may identify potentially actionable targets to prevent distant recurrence.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HRAS (Harvey rat sarcoma viral oncogene homolog) • NF1 (Neurofibromin 1)
|
TP53 mutation • HER-2 positive • PIK3CA mutation • HRAS mutation • NF1 mutation
|
Herceptin (trastuzumab) • cisplatin • carboplatin • paclitaxel
3ms
ETV6-NTRK3-positive parotid mammary analogue secretory carcinoma: a case report. (PubMed, Rom J Morphol Embryol)
It is necessary to establish an appropriated differential diagnosis between salivary gland tumors. MASC is a low-grade malignancy cancer that sometimes can evolve to a high-grade tumor that might produce local and distance dissemination. Most times, these tumors are only treated by surgical resection and evaluating by a multidisciplinary team the need of more treatments. In our case, the patient showed a primary parotid tumor, removed surgically with free edges, and being identified as MASC. We decided to underwent neck dissection and discovered a second MASC focus on cervical salivary gland; however, there was no nodal dissemination. The patient remains disease-free after 14 months from last surgery. It is important to keep studying genetic therapy targets to ETV6-NTRK3 to obtain a new therapy line to treat those cases that require.
Clinical • Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK3 fusion • ETV6-NTRK3 fusion • NTRK3 positive • NTRK positive
3ms
Identification of Salivary Gland Tumors (SGT) at Risk for Local or Distant Recurrence After Postoperative Radiation Therapy (PORT) With or Without Systemic Therapy (ST) Using Clinical Risk Grouping. (PubMed, Int J Radiat Oncol Biol Phys)
DM are the primary mode of recurrence in pts with resected SGT treated with PORT +/- ST and occurred only in high-risk pts. After randomized trials like RTOG 1008 determine the added benefit of chemo to PORT, DM is likely to remain an unmet need. Further studies incorporating molecular characterization of high-grade SGT may identify potentially actionable targets to prevent distant recurrence.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HRAS (Harvey rat sarcoma viral oncogene homolog) • NF1 (Neurofibromin 1)
|
TP53 mutation • HER-2 positive • PIK3CA mutation • HRAS mutation • NF1 mutation
|
Herceptin (trastuzumab) • cisplatin • carboplatin • paclitaxel
3ms
Detection of novel fusion genes by next-generation sequencing-based targeted RNA sequencing analysis in adenoid cystic carcinoma of head and neck. (PubMed, Oral Surg Oral Med Oral Pathol Oral Radiol)
Six novel gene fusions other than MYB/MYBL1-NFIB were identified. The detection of novel fusion genes and investigation of the molecular mechanism will contribute to the development of novel molecular targeted therapies for this disease.
Journal • Next-generation sequencing
|
NFIB (Nuclear Factor I B)
|
MYB-NFIB fusion
3ms
Reduction of Elective Radiotherapy Treatment Volume in Definitive Treatment of Locally Advanced Head and Neck Cancer-Comparison of a Prospective Trial with a Revised Simulated Contouring Approach. (PubMed, J Clin Med)
Treatment de-intensification by reduction of the irradiated volume could potentially reduce treatment volume and mean doses to organs at risk. The proposed contouring approach should be studied further in the context of a clinical trial.
Clinical • Journal
|
CD8 (cluster of differentiation 8)
3ms
Clear cell carcinoma: a comprehensive literature review of 254 cases. (PubMed, Int J Oral Maxillofac Surg)
Molecular features were reported in 113 cases; 96.0% were positive for an EWSR1 rearrangement by EWSR1 break apart FISH testing and 14.8% were positive for the rearrangement EWSR1-ATF1 tested by qPCR or targeted RNA sequencing. Clinical patterns and genetic studies imply that this tumor is the extraosseous counterpart of clear cell odontogenic carcinoma, an intraosseous odontogenic tumor of the jaws.
Clinical • Review • Journal
|
EWSR1 (EWS RNA Binding Protein 1) • ATF1 (Activating Transcription Factor 1) • TP63 (Tumor protein 63)
3ms
Salivary mucoepidermoid carcinoma: Histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features. (PubMed, Histopathology)
Recognition of the histological diversity of MEC, its clinicopathological features, and its associations with CRTC1/3-MAML2 fusions is helpful for an accurate diagnosis of this carcinoma.
Clinical • Journal
|
CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
CRTC1-MAML2 fusion
3ms
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. (PubMed, Cancer)
Adding systemic therapy to local therapy may improve outcomes of patients with locoregionally advanced SDC or adeno-NOS. Except for HER2-targeted therapy, response to palliative systemic therapy is limited. These findings may be used as a benchmark for future drug development.
Clinical • Journal
|
AR (Androgen receptor)
|
HER-2 positive • AR positive
|
Herceptin (trastuzumab)
3ms
Migration Stimulating Factor (MSF): Its Role in the Tumour Microenvironment. (PubMed, Adv Exp Med Biol)
Thus, different bioactive motifs and extracellular matrix requirements apply to fibroblasts, endothelial cells and tumour cells. Unlike other motogenic and angiogenic factors, MSF does not affect cell proliferation but it stimulates tumour growth through its angiogenic effect and downstream mechanisms.The epithelial-stromal pattern of expression and range of bioactivities displayed puts MSF in the unique position of potentially promoting tumour progression from both the "seed" and the "soil" perspectives.
Journal
|
FN1 (Fibronectin 1) • TGFB1 (Transforming Growth Factor Beta 1) • IGFBP7 (Insulin Like Growth Factor Binding Protein 7)
3ms
Overexpression of LAG3, TIM3 and A2aR in adenoid cystic carcinoma and mucoepidermoid carcinoma. (PubMed, Oral Dis)
These results suggested that LAG3, TIM3 and A2aR are overexpressed in AdCC and MEC, may promote migration of SACC-LM cell and correlated with TGF-β1 and oncogenic signaling pathways.
Journal • IO biomarker
|
LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)
|
HAVCR2 expression • LAG3 expression • LAG3 overexpression
3ms
Carcinoma showing thymus-like differentiation (CASTLE) of the salivary gland: Report of 2 cases of a hitherto under-recognized extrathyroid counterpart. (PubMed, Pathol Res Pract)
Salivary CASTLEs seem to show a wide range of biological behavior, and long-term follow-up may be needed. Immune checkpoint inhibitor targeting PD-1 might become a promising treatment option in patients with CASTLE; however, further study with a larger number of cases is necessary to establish the optimal therapeutic strategy and prognostic factors for this rare cancer.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD5 (CD5 Molecule)
|
PD-L1 expression
3ms
[VIRTUAL] A RARE INTRABRONCHIAL TUMOR PRESENTING WITH RECURRENT PNEUMONIA AND HEMOPTYSIS IN A YOUNG CHILD DURING THE COVID-19 PANDEMIC (CHEST 2021)
Our case presents a bronchial mucoepidermoid carcinoma in a child. Close follow up and recognition of uncommon findings led to the diagnosis of this rare cause of pneumonia in the midst of a global pandemic.
Clinical
|
NKX2-1 (NK2 Homeobox 1) • TP63 (Tumor protein 63) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
3ms
[VIRTUAL] A RARE FORM OF SYNCHRONOUS LUNG CANCER: MUCOEPIDERMOID CARCINOMA (CHEST 2021)
This case report serves to illustrate the rare combination of MEC and adenocarcinoma. Early surgical intervention has shown to be favorable in low-grade MEC; however, further investigation is required to evaluate for the need for adjunct therapy in the future given the risks of developing high-grade MEC and adenocarcinoma.
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • NKX2-1 (NK2 Homeobox 1) • TP63 (Tumor protein 63)
|
EGFR mutation • ALK mutation
3ms
Ex Vivo Drug Screening Informed Targeted Therapy for Metastatic Parotid Squamous Cell Carcinoma. (PubMed, Front Oncol)
The drug targets discovered on the basis of the ex vivo measured drug efficacy were validated with histopathology, genomic profiling, and in vitro cell biology methods, and targeted treatments with durable clinical responses were achieved. These results demonstrate the use of serial ex vivo drug screening to inform adjuvant therapy options prior to and during treatment and highlight HER2 as a potential therapy target also in metastatic squamous cell carcinoma of the salivary glands.
Preclinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
Kadcyla (ado-trastuzumab emtansine)
3ms
Secretory Carcinoma in Children and Young Adults: A Case Series. (PubMed, Pediatr Dev Pathol)
All cases underwent complete surgical resections and when follow up is available there was no evidence of recurrences or metastases. To the best of our knowledge, this is the only SC case series comprised exclusively of pediatric and youth patients.
Clinical • Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK3 fusion • ETV6-NTRK3 fusion
3ms
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov)
P1/2, N=12, Completed, University of Chicago | Active, not recruiting --> Completed
Clinical • Trial completion • Combination therapy
|
EGFR (Epidermal growth factor receptor)
|
Erbitux (cetuximab) • buparlisib (BKM120)
4ms
Journal
|
AR (Androgen receptor)
4ms
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. (PubMed, J Clin Oncol)
Abiraterone plus luteinizing hormone-releasing hormone agonist is active and safe as a second-line option in AR-expressing, castration-resistant SGC.
Clinical • P2 data • Journal
|
AR (Androgen receptor)
|
AR positive • AR overexpression • AR expression
|
abiraterone acetate • prednisone
4ms
Cytomorphologic fatures of intraductal salivary gland carcinoma: A multi-institutional study of 13 FNA cases with histologic, molecular, and clinical correlations. (PubMed, Cancer Cytopathol)
The cytomorphology of IDC overlaps with other benign and malignant salivary gland neoplasms. Immunohistochemistry limits the differential diagnosis, but definitive classification requires molecular analysis. A diagnosis of IDC has potential implications for patient management.
Clinical • Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RET (Ret Proto-Oncogene) • HRAS (Harvey rat sarcoma viral oncogene homolog) • AR (Androgen receptor) • NCOA4 (Nuclear Receptor Coactivator 4) • TP63 (Tumor protein 63)
|
PIK3CA mutation • RET fusion • HRAS mutation • NCOA4-RET fusion
4ms
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma (clinicaltrials.gov)
P2, N=40, Recruiting, Actuate Therapeutics Inc. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
BCL2 (B-cell CLL/lymphoma 2)
|
carboplatin • elraglusib (9-ING-41)
4ms
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells. (PubMed, Sci Rep)
In addition, Bortezomib modified the expression of proteasome structural subunits in transplanted SALTO-5 cells. Our findings further support the use of Bortezomib for the treatment of HNC and reveal its ineffectiveness in counteracting the activation of deregulated specific signaling pathways in HNC cell lines when resistance to proteasome inhibition is developed.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
bortezomib
4ms
Role of GATA3 in tumor diagnosis: A review. (PubMed, Pathol Res Pract)
GATA3 can also be used as a useful prognostic tool. Although GATA3 is a multi-specific immunohistochemical stain, it is a valuable marker in the panel for confirming many epithelial or mesenchymal neoplasms as both a diagnostic and prognostic tool.
Review • Journal
|
GATA3 (GATA binding protein 3)
4ms
[VIRTUAL] Recurrent Clear Cell Carcinoma of Minor Salivary Gland 18 Years After Primary Diagnosis: Cytology Case Report and Review of Literature (CAP 2021)
The keys to distinguish CCC on cytology are the proliferation of one type of epithelial cell with squamous differentiation, solid pattern, low-grade cytology, minimal atypia, vacuolated or clear cytoplasm, absence of myoepithelial or prominent mucinous differentiation, lack of mucinous stroma and obvious keratinization, and the support of a panel of immunohistochemical stains. Fewer than 10 cytology cases of CCC have been reported in literature.
Clinical • Review
|
TP63 (Tumor protein 63)
4ms
[VIRTUAL] Epithelial Myoepithelial Carcinoma: An Unusual Histologic Presentation With Oncocytic Low Grade Features (CAP 2021)
The use of myoepithelial/basal cell markers are often helpful in reaching the correct diagnosis in challenging cases, as demonstrated in this case. In addition, the concentric perinodular pattern of sclerosis seen in EMCA is somewhat distinct from the central scar in oncocytomas.
SOX10 (SRY-Box 10) • TP63 (Tumor protein 63)
4ms
[VIRTUAL] MAML2-Negative Oncocytic Mucoepidermoid Carcinoma of Submandibular Gland: A Rare Neoplasm (CAP 2021)
No rearrangement of the MAML2 gene on fluorescence in situ hybridization testing was identified, tested at 2 different centers. An awareness that MAML2 negative MEC exists will prevent misdiagnosis and incorrect treatment as many of its differentials are benign.
NKX2-1 (NK2 Homeobox 1) • PAX8 (Paired box 8) • TP63 (Tumor protein 63) • MAML2 (Mastermind Like Transcriptional Coactivator 2) • GATA3 (GATA binding protein 3)
4ms
[VIRTUAL] Mucinous Epithelium From the Nasal Sinuses: A Clinically Significant Differential Diagnosis (CAP 2021)
Fragments of pure mucinous epithelium are rare in sinonasal specimens and raise the differential diagnosis of the mucinous epithelium in respiratory adenomatoid hamartoma, intestinal-type sinonasal adenocarcinoma, and low-grade mucoepidermoid carcinoma. These lesions present as masses/polyps and are usually associated with abundant neoplastic epithelium with cytologic atypia. The reported cases appear to represent rare mucinous metaplasia with a benign course.
Clinical
|
CDX-2 • TP63 (Tumor protein 63)
4ms
[VIRTUAL] Oncocytic Lipoadenoma of the Parotid Gland: A Case Report and Focus on the Differential Diagnoses (CAP 2021)
However, lack of atypia and mitotic activity, as well as noninfiltrative growth (usually confirmed in the surgical excision) help to confirm the diagnosis. Other primary differential diagnoses include oncocytoma, Whartin tumor, and nodular oncocytic hyperplasia.
Clinical
|
PAX8 (Paired box 8) • TP63 (Tumor protein 63)
4ms
Diagnostic utility of p63/p40 in the histologic differentiation of salivary gland tumors: A systematic review. (PubMed, Oral Surg Oral Med Oral Pathol Oral Radiol)
The current evidence supports that integrated immunostaining of p63/p40 is a valuable adjunct for discerning enigmatic salivary gland tumors with true myoepithelial and/or squamous differentiation.
Review • Journal
|
TP63 (Tumor protein 63)
4ms
Sclerosing Polycystic Adenoma of Salivary Glands: A Novel Neoplasm Characterized by PI3K-AKT Pathway Alterations-New Insights Into a Challenging Entity. (PubMed, Am J Surg Pathol)
These prevalent molecular alterations converging on one major cancer-related pathway support the notion that SPA is a true neoplasm with a significant potential to develop intraluminal epithelial proliferation with apocrine and/or intercalated duct-like phenotype. The name SPA more correctly reflects the true neoplastic nature of this enigmatic lesion.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • AR (Androgen receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • SOX10 (SRY-Box 10)
|
PIK3CA mutation • PTEN mutation • HRAS mutation • AKT1 mutation
4ms
Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland Carcinoma. (PubMed, Front Oncol)
The expression of PD-L1 in tumor cells of high-grade SGCs was not uncommon, and it was significantly associated with tumor stage. PD-L1 expression in tumor cells rather than in immune cells indicated a poor prognosis.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
4ms
Journal
|
NR4A3 (Nuclear receptor subfamily 4 group A member 3)
4ms
Secretory Carcinoma of the Salivary Gland: A Rarity in Children. (PubMed, J Pediatr Hematol Oncol)
One patient was additionally found to have synchronous papillary thyroid carcinoma with a TFG-MET fusion. A review of published cases highlights the expanding molecular profile and confirms the favorable course of salivary gland SC after surgical resection.
Clinical • Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK3 fusion • ETV6-NTRK3 fusion • MET fusion
5ms
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene (clinicaltrials.gov)
P1/2, N=82, Recruiting, Klus Pharma Inc. | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
A166
5ms
Characterization of tumor-associated MUC1 and its glycans expressed in mucoepidermoid carcinoma. (PubMed, Oncol Lett)
These data were obtained from the soluble fractions of salivary gland homogenates. These findings provide a basis for the utilization of MUC1 as a serum diagnostic marker for the preoperative diagnosis of MEC.
Journal
|
MUC1 (Mucin 1)
5ms
[VIRTUAL] Case report: a 47-year-old man with a primary intraosseous carci- noma, NOS (ECP 2021)
PIOC is a diagnosis of exclusion. This aggressive central jaw carcinoma, assumed to derive from the odontogenic epithelium needs differential diagnosis with metastases, squamous odontogenic tumour, solid odontogenic keratocyst, keratinizing ameloblastoma and central high-grade mucoepidermoid carcinoma. Histopathological, clinical and radiographic features assure an accurate diagnosis.
Clinical
|
KRT19 (Keratin 19) • TP63 (Tumor protein 63)
5ms
[VIRTUAL] Fine needle aspiration primary squamous cell carcinoma of the pa- rotid gland (ECP 2021)
The cytological diagnosis of primary parotid gland tumour is effective, when the morphological, as well as the immunostaining results are taken into account and may contribute to the patient’s clinical treatment.
TP63 (Tumor protein 63)
5ms
[VIRTUAL] Pulmonary mucous gland adenoma. A case report (ECP 2021)
Experienced pathologists should keep PGMA in mind since its differential diagnosis includes both benign and malignant entities. The collaboration of radiologists, pneumonologists and pathologists along with thorough sampling and immunohistochemical assays is mandatory for the accurate pathological diagnosis and appropriate therapy of the patient.
Clinical
|
NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
5ms
[VIRTUAL] Acinic cell carcinoma of the breast: a case report of a rare triple negative breast cancer with unusual clinical course (ECP 2021)
ACC is an exceedingly rare type of low grade TNBC that is generally associated with indolent behaviour. This case, however, showed an unusual clinical outcome with early recurrence. The association with atypical microglandular adenosis is interesting as both lesions have been found to share similar molecular abnormalities, which supports their clonal relationship.
Clinical
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • SOX10 (SRY-Box 10) • NTRK (Neurotrophic receptor tyrosine kinase) • GATA3 (GATA binding protein 3)
5ms
[VIRTUAL] Adenoid cystic carcinoma of the breast. A case report and literature review (ECP 2021)
ACC is an unusual type of breast carcinoma accounting for <0.1% of breast malignancies. It is characterized by a biphasic population of luminal and basaloid cells with pseudolumens filled with basement membrane material. The mean age at diagnosis is 66 years.
Clinical • Review
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • TP63 (Tumor protein 63) • MME (Membrane metallo-endopeptidase)
5ms
[VIRTUAL] The first experience of NTRK testing in Russia. Multicentre research (ECP 2021)
The first NTRK multicentre research have found 8.7% IHC panTRK-positive tumours. Positive staining with confirmed NTRK fu- sion was seen in thyroid carcinoma, breast and salivary gland secretory carcinoma and infantile fibrosarcoma and mesoblastic nephroma.
Clinical
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion • NTRK positive
|
VENTANA pan-TRK (EPR17341) Assay
5ms
[VIRTUAL] The importance of EGFR gene amplification in the malign salivary gland tumours (ECP 2021)
EGFR mutations in salivary gland tumours are rare, how- ever, EGFR amplification has been reported in the literature at a rate of 5- 14%. We found the EGFR amplification as 13,6% in this study. EGFR amplification is common in early-stage and female patients under 65 years of age and the mortality rate is higher in these cases.
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR amplification
5ms
[VIRTUAL] Cribriform adenocarcinoma of the minor salivary glands: an entity on the rise (ECP 2021)
There is still much debate if the cribriform adenocarcinoma of the minor salivary glands is a separate entity from polymorphous adenocarcinoma, a variant or if they are both part of a same morphologic spectrum. Both harbour genetic changes in the PRKD1, PRKD2 and PRKD3 genes, although these are essentially translocations in the former and somatic point mutations in the latter. Most importantly, cribriform adenocarcinoma metastasizes more frequently to the cervical lymph nodes (50% at presentation), requiring lymph node dissection.
NKX2-1 (NK2 Homeobox 1) • SOX10 (SRY-Box 10) • PRKD1 (Protein Kinase D1)
5ms
YATAGARASU: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (clinicaltrials.gov)
P2, N=31, Active, not recruiting, Janssen Pharmaceutical K.K. | Trial completion date: Oct 2022 --> Jan 2023
Clinical • Trial completion date • Combination therapy
|
AR (Androgen receptor)
|
AR positive • AR expression
|
Erleada (apalutamide) • goserelin acetate
5ms
Sclerosing microcystic adenocarcinoma of the parotid gland - The first recorded case with histo-cytopathologic correlation and a brief review of the literature. (PubMed, Ann Diagn Pathol)
On immunohistochemistry, EMA, SOX-10, P63, and S-100 protein highlighted a dual cell population of luminal and abluminal cells. The cells were negative for CD117, and the Ki-67 proliferation index was low (<5%).
Clinical • Review • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • SOX10 (SRY-Box 10) • TP63 (Tumor protein 63)
5ms
Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature. (PubMed, Head Neck Pathol)
Coexisting PTEN mutations were seen in 4 cases, including in a patient with clinical stigmata of Cowden syndrome and confirmed by germline genetic testing. Our findings herein documented including recurrence of tumor, malignant transformation, high prevalence of PI3K pathway oncogenic alterations and the possible heretofore undescribed association with Cowden syndrome add support to classifying SPA as true neoplasms justifying their designation as adenoma, rather than adenosis.
Clinical • Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1)
|
PIK3CA mutation • PTEN mutation • PTEN expression
5ms
Mucoepidermoid carcinoma of the head and neck: CRTC1/3 MAML 2 translocation and its prognosticators. (PubMed, Eur Arch Otorhinolaryngol)
MEC of the head and neck has a favorable outcome with the exception of high-grade MEC. PNI and nodal involvement are not rare. CRTC1/3 MAML 2 fusion gene presence showed no survival benefit. The tendency for late onset of loco-regional and distant recurrence should not be underestimated.
Journal
|
CRTC1 (CREB Regulated Transcription Coactivator 1)
5ms
DART: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
P2, N=818, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Aug 2021 --> Aug 2022
Clinical • Trial primary completion date
|
CD4 (CD4 Molecule)
|
PD-L1 overexpression • PD-L1 amplification
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
5ms
Molecular mechanism underlying the apoptotic modulation by ethanol extract of Pseudolarix kaempferi in mucoepidermoid carcinoma of the salivary glands. (PubMed, Cancer Cell Int)
This study revealed that EEPK-induced alterations of Mcl-1 inhibition and JNK/Bcl-2 phosphorylation cause apoptosis and provided basic preclinical data for future clinical trials regarding therapy for patients with MEC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MAPK8 (Mitogen-activated protein kinase 8)
|
BCL2 expression • MCL1 expression
5ms
Diagnostic value of biomarkers of bone metabolism in the gingival fluid in inflammatory-destructive and tumor oral pathology (PubMed, Stomatologiia (Mosk))
Thus, biochemical markers are sensitive indicators of remodeling of bone tissue both in local inflammatory and destructive processes in peri-implantitis and in primary and metastatic tumor lesions of the jaws.
Journal
|
CTSK (Cathepsin K)
5ms
Mutually Exclusive Expression of COL11A1 by CAFs and Tumour Cells in a Large panCancer and a Salivary Gland Carcinoma Cohort. (PubMed, Head Neck Pathol)
Our findings represent a novel mode of extracellular matrix production in carcinomas and could be highly relevant in the future. Our findings elucidate the mode of COL11A1 expression in very different carcinoma types and may aid to categorise tumours in the setting of possible future COL11A1-related therapies.
Journal • Pan tumor
|
COL1A1 (Collagen, type I, alpha 1)
5ms
Immunological and biological dissection of normal and tumoral salivary glands. (PubMed, Int Rev Immunol)
Chemokines and chemokine receptors have influential roles on aggressive behaviors of SGTs, and thereby they could be candidate targets for cancer immunotherapy. To present a broad knowledge on salivary glands, this review first provides a brief description on immunological functions of normal salivary glands, and then describe the SGT's tumor microenvironment, by focusing on mesenchymal stem cells, immune cell subsets, immune checkpoint molecules, chemokines and chemokine receptors, and finally introduces immune checkpoint inhibitors as well as potential targets for cancer therapy.
Journal • IO biomarker
|
LAG3 (Lymphocyte Activating 3)
|
LAG3 expression
5ms
Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report. (PubMed, Diagn Pathol)
Our findings underline the importance to be aware of non-canonical signal patterns during FISH analysis for detection of NTRK rearrangements. Very faint single 3' signals can indicate a functional NTRK rearrangement and therefore be of high predictive value.
Clinical • Journal
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK1 fusion • NTRK2 fusion • NTRK expression • NTRK fusion
|
Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)
5ms
Mutational landscape of primary pulmonary salivary gland-type tumors through targeted next-generation sequencing. (PubMed, Lung Cancer)
These results explain PSGTs harbor distinct driver features of MAML2 or MYB rearrangement, accompanied with wide mutational diversity with very low rate of somatic mutation. Several important pathways, including the NOTCH and PI3K pathways, and chromatin remodeling could be targeted to improve the survival in patients with ACC.
Journal • Next-generation sequencing • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • FGFR1 (Fibroblast growth factor receptor 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • ASXL1 (ASXL Transcriptional Regulator 1) • PD-1 (Programmed cell death 1) • KMT2A (Lysine Methyltransferase 2A) • FLT1 (Fms-related tyrosine kinase 1) • RBM10 (RNA Binding Motif Protein 10) • PTPRD (Protein tyrosine phosphatase receptor type D) • INPP4B (Inositol polyphosphate-4-phosphatase type II B) • FOXP1 • CCND2 (Cyclin D2) • NOTCH4 (Notch 4) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
HRAS mutation • ASXL1 mutation • FGFR1 mutation • PTPRD mutation
5ms
[VIRTUAL] Warthin-like mucoepidermoid carcinoma - a morphologic spectrum: report of 3 cases with histological and cytological findings and review of the literature (ECP 2021)
Differentiating WT-like MECs from ordinary WTs may be challenging. On one end of the spectrum they may look very much like WT, on the other end, even though usual MEC features are present, still WT-like appearance may pose diagnostic difficulty. Showing MAML2 rearrangement in these cases is very helpful.
Clinical • Review
|
MAML2 (Mastermind Like Transcriptional Coactivator 2)
5ms
[VIRTUAL] Secretory carcinoma of the parotid gland: a tumour with many diagnostic clues (ECP 2021)
Cytological diagnosis of salivary gland tumours possess major challenge, even for head and neck specialists. Diagnosing a rare tumour like secretory carcinoma requires a high index of suspicion and awareness of its characteristic cytological and histological diagnostic fea- tures. Confirming ETV6-NTRK3 fusion remains the gold standard for diagnosis, which can be done on both cell block and tissue samples.
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK3 fusion • ETV6-NTRK3 fusion
5ms
MAML2 gene rearrangement, fusion patterns and clinicopathological characteristics in primary pulmonary mucoepidermoid carcinoma (PubMed, Zhonghua Bing Li Xue Za Zhi)
RNAseq confirms that CRTC1/3-MAML2 is the main fusion pattern in PMEC, suggesting that MAML2 fusion transcription may be an important driving factor of PMEC. MAML2 rearrangement/fusion and related clinicopathological characteristics are associated with good prognosis.
Clinical • Journal
|
CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
CRTC1-MAML2 fusion
5ms
Secretory carcinoma of salivary gland: a clinicopathological and prognostic analysis of twelve cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
In molecular detection, 11 cases had ETV6 gene break/fusion. SCSG is a relatively rare low-grade malignant salivary gland tumor, with typical histological morphology and immunophenotype, Pan-Trk immunohistochemistry may be related to NTRK fusion, ETV6-NTRK3 gene rearrangement is not only of diagnostic significance, but also Trk-targeted therapy is expected to play a greater role in clinical treatment.
Clinical • Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • SOX10 (SRY-Box 10) • NTRK (Neurotrophic receptor tyrosine kinase) • GATA3 (GATA binding protein 3)
|
ETV6-NTRK3 fusion • NTRK fusion
6ms
Malignant salivary gland tumours in families with breast cancer susceptibility. (PubMed, Virchows Arch)
Loss of heterozygosity of BRCA wild-type alleles was assessed in the patients' tumour DNA. We conclude that our observations support the hypothesis that genetic factors associated with BC susceptibility might play a role also in at least a subset of SGCs.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA1 mutation • BRCA mutation
6ms
[VIRTUAL] Secretory Carcinoma; Review of 10 Years World-wide Experience and Meta-analysis (AHNS 2021)
Secretory Carcinoma is a rare and relatively newly defined entity. The majority of patients are diagnosed at an early stage, without regional or distant disease, and perineural invasion is uncommon. About a third of the patients receive adjuvant radiotherapy and the prognosis is relatively good, with a recurrence rate of 19.5% and disease-related mortality of 17.8%.
Retrospective data • Review
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
ETV6-NTRK3 fusion
6ms
[VIRTUAL] Androgen Deprivation Therapy for Advanced or Recurrent Salivary Gland Carcinoma: A Systematic Review (AHNS 2021)
Existing data for the use of ADT in advanced SGC is promising. Further optimization and standardization of protocols is needed, ideally in the form of prospective controlled trials.
Review
|
AR (Androgen receptor)
|
AR positive
6ms
[VIRTUAL] Targeting cancer stem cells with mTOR inhibitors in mucoepidermoid carcinoma (AHNS 2021)
Materials and Methods The effect of an mTOR inhibitor (temsirolimus) on resistance of MEC CSCs to cisplatin was evaluated in a panel of human MEC cell lines (UM-HMC-1, UM-HMC-3A, UM-HMC-3B), and using a patient-derived xenograft (PDX) model of MEC (UM-HMC-PDX-18). Nakano); Soda Toyoji Memorial Foundation (T. Nakano).
CD44 • BMI1 (BMI1 proto-oncogene, polycomb ring finger)
|
BMI1 expression
|
cisplatin • Torisel (temsirolimus)
6ms
Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report. (PubMed, Anticancer Drugs)
Combined chemotherapy with doxorubicin, carboplatin and cyclophosphamide was applied for two cycles but ineffective. At recent follow-ups, MRI and CT examinations revealed the diminishing perianal and pulmonary lesions. This study presented the first case of perianal ACC with multiple pulmonary metastases and particular BCOR mutations, who presented a durable response to eribulin and anlotinib, providing a potential therapeutic option for advanced refractory ACC.
Clinical • Journal
|
BCL6 (B-cell CLL/lymphoma 6) • BCOR (BCL6 Corepressor) • NFIB (Nuclear Factor I B)
|
BCOR mutation
|
carboplatin • Focus V (anlotinib) • doxorubicin hydrochloride • Halaven (eribulin mesylate)
6ms
HMGA2-WIF1 Rearrangements Characterize a Distinctive Subset of Salivary Pleomorphic Adenomas With Prominent Trabecular (Canalicular Adenoma-like) Morphology. (PubMed, Am J Surg Pathol)
Our data confirm that canalicular adenomas in major salivary glands (either monomorphic or part of hybrid tumors) are distinct from canalicular adenoma of minor salivary glands. Their uniform genotype irrespective of presence or absence of a conventional PA component argues for classifying those tumors lacking a conventional PA component as "monomorphic variants of PA" rather than canalicular/basal cell adenomas, intercalated duct adenoma, trabecular myoepithelioma or true hybrid tumors.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • LIFR (LIF Receptor Subunit Alpha) • SOX10 (SRY-Box 10) • MUC4 (Mucin 4, Cell Surface Associated) • NFIB (Nuclear Factor I B) • VIM (Vimentin) • TP63 (Tumor protein 63) • WIF1 (WNT Inhibitory Factor 1) • HMGA2 (High mobility group AT-hook 2)
|
FGFR1 fusion • VIM expression
6ms
Wnt Family Member 9b (Wnt9b) Is a New Sensitive and Specific Marker for Breast Cancer. (PubMed, Am J Surg Pathol)
For nonbreast tumors, including 64 cases of urothelial carcinoma, Wnt9b was negative in all except salivary gland carcinomas. The study demonstrated that Wnt9b is a breast cancer marker with similar sensitivity as GATA3 but with greater specificity than GATA3 and may ultimately become a useful diagnostic tool in routine surgical pathology practice.
Journal
|
ER (Estrogen receptor) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • GATA3 (GATA binding protein 3)
6ms
Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade. (PubMed, Cancers (Basel))
mRNA from 76 R/M androgen receptor (AR)-positive SDC patients treated with leuprorelin acetate combined with bicalutamide was extracted from pre-treatment tumor specimens...SRD5A1 expression can identify patients that will and AR PAS patients that will not experience clinical benefit (85.7% and 93.3% for PPV and NPV, respectively). The predictive potential of SRD5A1 expression forms a rational basis for including SRD5A1-inhibitors in SDC patients' treatment.
Clinical • Journal
|
ER (Estrogen receptor) • AR (Androgen receptor) • TGFB1 (Transforming Growth Factor Beta 1)
|
AR positive
|
bicalutamide
6ms
Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • pemetrexed
6ms
Some Pleomorphic Adenomas of the Breast Share PLAG1 Rearrangements with the Analogous Tumor of the Salivary Glands. (PubMed, Histopathology)
Breast PA is rare, but it is an important differential diagnosis of breast pathology with the potential to develop carcinoma ex PA. We reported a novel TRPS1-PLAG1 fusion gene in breast PA.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • HMGA2 (High mobility group AT-hook 2) • TRPS1 (Transcriptional Repressor GATA Binding 1)
6ms
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. (PubMed, NPJ Precis Oncol)
We investigated the prevalence and concomitant genomic landscape of NTRK fusions, predicted patient ancestry and compared the FoundationCORE cohort with entrectinib clinical trial cohorts (ALKA-372-001 [EudraCT 2012-000148-88]; STARTRK-1 [NCT02097810]; STARTRK-2 [NCT02568267])...NTRK gene fusion prevalence varied greatly by age, cancer type and histology. Interrogating large datasets drives better understanding of the characteristics of very rare molecular subgroups of cancer and allows identification of genomic patterns and previously unreported fusion partners not evident in smaller datasets.
Clinical • Journal • Real-world evidence
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF mutation • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • NTRK1 positive • NTRK fusion • NTRK positive
|
Rozlytrek (entrectinib)
6ms
[VIRTUAL] Case series of docetaxel, trastuzumab, and pertuzumab (DTP) and subsequent ado-trastuzumab emtansine (T-DM1) for recurrent or metastatic (R/M) HER2-positive salivary duct carcinoma (SDC) (ESMO 2021)
In R/M HER2-positive SDC patients DTP followed by T-DM1 upon progression are promising treatment strategies, leading to responses in the majority of the patients at an acceptable toxicity profile. The median OS was not reached after a median follow-up of 15.4 months.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
|
HER-2 positive • AR positive
|
Herceptin (trastuzumab) • docetaxel • Kadcyla (ado-trastuzumab emtansine) • Perjeta (pertuzumab)
6ms
[VIRTUAL] Phase II study of PI3K inhibitor copanlisib in cancer patients with deleterious PTEN mutations and retained PTEN protein expression: Results from the NCI-MATCH Trial (EAY131) sub-protocol Z1H (ESMO 2021)
of arm Z1H of the NCI-MATCH trial demonstrated that single agent copanlisib has limited activity in cancers with deleterious PTEN mutation without loss of expression.
Clinical • P2 data
|
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog)
|
TP53 mutation • PTEN mutation • PTEN deletion • PTEN expression • PTEN mutation + TP53 mutation
|
Aliqopa (copanlisib)
6ms
[VIRTUAL] ACE1702, a first-in-class, off-the-shelf, selected natural killer cell [oNK] product using antibody cell conjugation technology [ACC], with pre-clinical and early clinical activity in HER2 < 3+ tumors (ESMO 2021)
In pre-clinical studies, ACE1702 exhibited cancer-specific cytotoxicity and superior potency against low HER2 tumors. Preliminary data in pts showed no CRS, GvHD, or DLTs through doses of 3B cells/cycle and antitumor activity in a HER2 < 3+ tumor. Dose escalation continues up to 15B cells/cycle with updated clinical data to be provided.
Preclinical
|
HER-2 (Human epidermal growth factor receptor 2) • IL6 (Interleukin 6) • IFNG (Interferon, gamma) • IL10 (Interleukin 10)
|
ACE1702
6ms
[VIRTUAL] First-results of the CLIMB360 study, a prospective molecular screening program across multiple cancer types based on circulating tumor DNA (ctDNA) (ESMO 2021)
Real-time and prospective genomic profiling of pts with advanced cancer using ctDNA is feasible, fast and helps to identify therapeutic targets approved or evaluated in clinical trials.
Clinical • MSi-H Biomarker • Circulating tumor DNA
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Guardant360® CDx
6ms
iPRIME: Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors (clinicaltrials.gov)
P2, N=46, Recruiting, University of Chicago | Trial primary completion date: Jun 2021 --> Sep 2021
Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • docetaxel
6ms
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma (clinicaltrials.gov)
P2, N=40, Not yet recruiting, Actuate Therapeutics Inc. | Initiation date: Jun 2021 --> Sep 2021
Clinical • Trial initiation date
|
BCL2 (B-cell CLL/lymphoma 2)
|
carboplatin • elraglusib (9-ING-41)
6ms
Expression of Transcription Factor CREM in Human Tissues. (PubMed, J Histochem Cytochem)
A transcriptomic analysis of normal tissues and cancer showed that transcription of CREM can be altered in tumors, suggesting that also wild-type CREM may be involved in cancer biology. The wide expression of CREM protein in normal human tissues and cancer may limit the utility of immunohistochemistry for identification of tumors with CREM fusions.
Journal
|
EWSR1 (EWS RNA Binding Protein 1)
6ms
An Underappreciated Cytomorphological Feature of Secretory Carcinoma of Salivary Gland on Fine Needle Aspiration Biopsy: Case Report with Literature Review. (PubMed, Head Neck Pathol)
In this article, we review the literature pertaining to SC cytomorphology and we report a fine needle aspiration biopsy case of SC in salivary gland showing well-defined intracytoplasmic hyaline globules, a feature that has not been previously reported. This novel cytomorphological feature may be helpful in distinguishing the tumor cells of SC from histiocytes and from other low-grade salivary gland tumors.
Clinical • Review • Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK3 fusion • ETV6-NTRK3 fusion
6ms
HER-2 Neu gene: A valuable therapeutic target in metastatic mucoepidermoid carcinoma. (PubMed, J Oncol Pharm Pract)
The metastatic MEC in our patient overexpressed HER-2 Neu. Owing to Trastuzumab and Pertuzumab response, Trastuzumab emtansine (TDM-1) was initiated on a compassionate basis which further extended the survival but had to be terminated owing to adverse effects. Given the paucity of data on targeted therapies in the treatment of metastatic SGNs and the safety, tolerability, and efficacy of TDM-1 therapy among the elderly, further studies are warranted to answer these important questions and to identify eligible patients for this novel treatment option.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression
|
Kadcyla (ado-trastuzumab emtansine) • Perjeta (pertuzumab)
6ms
HER2 Positivity in Histological Subtypes of Salivary Gland Carcinoma: A Systematic Review and Meta-Analysis. (PubMed, Front Oncol)
Estimates for five additional subtypes were assessed. Prevalence of HER 2 positivity in SGC varies greatly based on histological subtype, with SDC, CEP, SCC, and ADC displaying the highest rates.
Retrospective data • Review
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
6ms
Clear Cell Carcinoma in the Oral Cavity with Three Novel Types of EWSR1-ATF1 Translocation: A Case Report. (PubMed, Head Neck Pathol)
Herein, we report an interesting case of CCC harboring three EWSR1-ATF1 translocations: EWSR1 exon 8-ATF1 exon 4, EWSR1 exon 7-ATF1 exon 4, and EWSR1 exon 7-ATF1 exon 5. This case indicates the possibility of independent EWSR1-ATF1 gene translocations, and could provide insight into CCC tumorgenesis.
Clinical • Journal
|
EWSR1 (EWS RNA Binding Protein 1) • ATF1 (Activating Transcription Factor 1)
6ms
Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1/3-MAML2 genotyping. (PubMed, Virchows Arch)
However, their significance regarding young age (≤ 30 years) and location-dependent heterogeneity of in particular G2-tumors is more questionable. We conclude that CRTC1/3-MAML2 testing is a useful adjunct to histologic scoring of MECs and for pinpointing tumors with poor prognosis with higher precision, thus avoiding overtreatment.
Journal
|
CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
7ms
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (clinicaltrials.gov)
P1, N=15, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Mar 2023 --> Mar 2026 | Trial primary completion date: Mar 2023 --> Mar 2026
Clinical • Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
|
CD4 (CD4 Molecule)
|
HER-2 positive • HER-2 amplification • HER-2 expression
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)
7ms
Immunohistochemical expression of OCT4 and CD44 in major and minor salivary gland neoplasms. (PubMed, Braz Oral Res)
A significant moderate positive correlation (r = 0.444 and p ≤ 0.001) was found between OCT4 and CD44 immunoexpression in the total sample. The high expression of OCT4 and CD44 may indicate that these proteins play an important role in identifying tumor stem cells.
Journal
|
CD44 • POU5F1 (POU Class 5 Homeobox 1)
|
CD44 expression • POU5F1 expression
7ms
Metastatic malignant melanoma mimicking a salivary gland basaloid neoplasm after treatment with nivolumab. (PubMed, Diagn Cytopathol)
Nivolumab was then stopped, Dabrafenib/Trametinib were started, and the patient underwent excision of the nodules. This report emphasizes that melanoma involving the parotid gland region has the potential to be misdiagnosed by FNA as a salivary gland neoplasm because of overlapping cytologic features and immunophenotypes. This pitfall is avoided by careful morphologic analysis and judicious use of ancillary studies.
Journal
|
SOX10 (SRY-Box 10) • MITF (Melanocyte Inducing Transcription Factor) • TP63 (Tumor protein 63) • HMGA2 (High mobility group AT-hook 2)
|
Opdivo (nivolumab) • Mekinist (trametinib) • Tafinlar (dabrafenib)
7ms
Targeted RNA Sequencing in the Routine Clinical Detection of Fusion Genes in Salivary Gland Tumors. (PubMed, Genes Chromosomes Cancer)
Finally, as anticipated, gene fusions were not detected in any of the five acinic cell carcinomas included in the cohort. In summary, targeted RNA sequencing represents a diagnostically useful ancillary technique for identifying a variety of existing, and novel, fusion transcripts in the classification of salivary gland neoplasms.
Clinical • Journal
|
NFIB (Nuclear Factor I B) • CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2) • HMGA2 (High mobility group AT-hook 2)
7ms
Expression of PLAG1, HMGA1 and HMGA2 in minor salivary glands tumours. (PubMed, Gland Surg)
In this study we assessed the diagnostic role of PLAG1, HMGA1 and HMGA2 immunohistochemical analysis. The score panel facilitate histopathological diagnosis of these rare tumours, helping to distinguish benign tumours from malignant ones and ameliorating the differential diagnosis of specific histotypes.
Journal
|
HMGA2 (High mobility group AT-hook 2)
7ms
Degenerative nuclear atypia in pleomorphic adenoma of salivary glands: Histological and immunohistochemical observations. (PubMed, Pathol Res Pract)
Degenerative nuclear atypia in PA seems rare, associated with non-cycling, non-luminal cells of myomatous ('myoepithelial') or schwannomatous phenotype and not related to malignant transformation. The particular phenotype of the affected cells suggests similarities to the degenerative nuclear atypia in pleomorphic leiomyoma and ancient schwannoma.
Journal
|
WT1 (WT1 Transcription Factor) • TP63 (Tumor protein 63)
7ms
YATAGARASU: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (clinicaltrials.gov)
P2, N=31, Active, not recruiting, Janssen Pharmaceutical K.K. | Trial completion date: Jul 2021 --> Oct 2022
Clinical • Trial completion date • Combination therapy
|
AR (Androgen receptor)
|
AR positive • AR expression
|
Erleada (apalutamide) • goserelin acetate
7ms
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. (PubMed, Eur J Nucl Med Mol Imaging)
An overview of the (pre)clinical data on PSMA immunohistochemistry and PSMA PET/CT imaging is provided and summarized. Furthermore, the first clinical reports of non-prostate cancer patients treated with PSMA-RLT are described.
Clinical • Review • Journal
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 expression
7ms
Expressions of CXCL12, CXCL10 and CCL18 in Warthin tumors characterized pathologically by having a lymphoid stroma with germinal centers. (PubMed, Histol Histopathol)
Finding CXCL12 and CXCL10 expressions indicate that these chemokines may play a part in the formation of a lymphoid stroma within Warthin tumors. In regards to this phenomenon, the participation of CCL18 might be restrictive compared to CXCL12 and CXCL10.
Journal
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
7ms
Myoepithelial Carcinoma Ex-Pleomorphic Adenoma: A Rare Pathology Misdiagnosed as Pleomorphic Adenoma; With a Novel TERT Promoter Mutation and High PD-L1 Expression. (PubMed, Head Neck Pathol)
This case highlights importance of recognizing the subtle malignant features of MECA in distinguishing it from benign mimics like PA. In addition, presence of TERT mutation opens a new arena for future research to explore potential treatment targets.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TERT (Telomerase Reverse Transcriptase) • TP63 (Tumor protein 63)
|
PD-L1 expression • PD-L1 overexpression • TERT promoter mutation • TERT mutation
7ms
Mammary Lobular Carcinoma-Like Salivary Gland Carcinoma: Report of a Rare Case. (PubMed, Head Neck Pathol)
The patient was treated with surgical resection, immunotherapy, and chemotherapy. Currently, he is alive with disease twenty months after disease onset.
Clinical • Journal • IO biomarker
|
CDH1 (Cadherin 1) • CTNNA1 (Catenin Alpha 1)
8ms
[VIRTUAL] Topics for discussion (ASCO 2021)
Risk factors (e.g., tobacco/alcohol consumption, exposure to environmental pollutants) for the development of head and neck cancer Diagnosis, screening and prevention strategies in SCCHN; molecular biomarkers and key pathways in the development and progression of SCCHN Clinical factors (e.g., pre-existing comorbidities, performance status and pathologic features) to consider when designing a therapeutic plan for patients with SCCHN Role of the human papillomavirus (HPV) in the development of head and neck cancers; impact of HPV status on the use of immune checkpoint inhibitors in SCCHN Factors guiding the selection of therapy for patients with SCCHN; influence of prior treatment, time since completion of definitive treatment, age, symptomatology, extent of metastases and PD-L1 expression status in the choice of treatment regimen Clinical role of concurrent and/or induction chemotherapy with radiation therapy for patients presenting with locoregional SCCHN Published research data with and current clinical role of cetuximab for patients with localized, recurrent or metastatic SCCHN; role of EGFR targeted therapies in the era of immunotherapy Prevalence and clinical implications of EGFR mutations in progressive SCCHN; recent FDA approval of a new dosage regimen for cetuximab Spectrum, frequency and severity of toxicities observed with cetuximab in combination with platinum-based chemotherapy; strategies to mitigate the associated side-effects Clinical utility of microsatellite instability (MSI) testing and PD-L1 status determinations using the tumor proportion score (TPS) and/or the combined positive score (CPS) for patients with SCCHN; similarities and differences in the available PD-L1 assay platforms Key efficacy and safety results supporting the FDA approval of pembrolizumab as first-line therapy in the Phase III KEYNOTE-048 trial for recurrent or metastatic SCCHN Optimal management of disease that progresses on pembrolizumab when administered as first-line therapy either alone or in combination with chemotherapy for patients with PD-L1-positive SCCHN Research databases supporting the use of immune checkpoint inhibitors for patients SCCHN; identification of patients with SCCHN who are ineligible for immune checkpoint inhibitor therapy Mechanism of action of and emerging results with camrelizumab alone or in combination with chemotherapy for recurrent or metastatic head and neck cancers Results from the Phase III KESTREL and EAGLE trials of the anti-PD-L1 antibody durvalumab with or without tremelimumab versus standard of care treatment for patients with recurrent or metastatic SCCHN Biologic rationale for the investigation of bempegaldesleukin in combination with pembrolizumab in a Phase II/III trial for patients with head and neck cancer whose tumors express PD-L1 CPS or 1 or more Updated results from the Phase III JAVELIN Head and Neck 100 study of avelumab in addition to chemoradiotherapy (CRT) versus CRT alone for untreated locally advanced SCCHN; recommendations for study termination Recognition, incidence, monitoring and optimal management of immune-related adverse events in patients receiving immune checkpoint inhibitor therapy Mechanisms of resistance to EGFR inhibition and immune checkpoint inhibition in SCCHN Mechanism of action of tipifarnib and published data with this agent in the Phase II RUN-HN trial in the cohort of patients with HRAS-mutant recurrent and/or metastatic SCCHN after disease progression on platinum-based chemotherapy; recent FDA breakthrough therapy designation Role of entrectinib and Larotrectinib in patients with NTRK gene fusion-positive salivary gland carcinomas Mechanism of action and rationale for the ongoing investigation of xevinapant in the Phase III TrilynX study for previously untreated high-risk locally advanced SCCHN
PD(L)-1 Biomarker • IO biomarker
|
MSI (Microsatellite instability) • HRAS (Harvey rat sarcoma viral oncogene homolog) • NTRK (Neurotrophic receptor tyrosine kinase)
|
PD-L1 expression • EGFR mutation • HRAS mutation • NTRK fusion
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Imfinzi (durvalumab) • Bavencio (avelumab) • AiRuiKa (camrelizumab) • tremelimumab (CP-675206) • Zarnestra (tipifarnib) • bempegaldesleukin (NKTR-214) • xevinapant (AT-406)
8ms
PAX-8 Expression in Salivary Duct Carcinoma. (PubMed, Appl Immunohistochem Mol Morphol)
Therefore, we conclude that although the majority of SDC are negative for PAX-8, rare diffuse positivity can be seen in these primary salivary gland tumors. This could potentially pose difficulty in ruling out metastatic disease from another PAX-8-positive primary neoplasm.
Journal
|
AR (Androgen receptor) • PAX8 (Paired box 8)
|
AR expression • PAX8 positive
8ms
Cancer Stem Cell Markers in Squamous Cell Carcinomas of the Salivary Glands. (PubMed, Oncology)
CD-44 and ALDH-1 may be useful in differentiating between primary SCCs and metastatic disease. BMI-1 and SOX-2 are correlated with poorer prognosis.
Retrospective data • Journal
|
CD44 • BMI1 (BMI1 proto-oncogene, polycomb ring finger) • SOX2 • VIM (Vimentin) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1)
|
BMI1 expression • VIM expression
8ms
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer (clinicaltrials.gov)
P2, N=64, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2021 --> May 2022 | Trial primary completion date: May 2021 --> May 2022
Clinical • Trial completion date • Trial primary completion date
|
AR (Androgen receptor)
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
8ms
Oncocytic Lipoadenoma: Report of 3 Rare Cases Involving the Parotid Gland, Including a Synchronous Presentation With Paraganglioma of the Right Carotid Bifurcation and Literature Review. (PubMed, Int J Surg Pathol)
Despite distinctive morphologic features, OL is often misdiagnosed, given its rarity. We hope to contribute to surgeons' and pathologists' awareness and knowledge regarding the existence of this tumor and provide adequate management through conservative surgical excision.
Clinical • Review • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • VIM (Vimentin) • KRT19 (Keratin 19) • TP63 (Tumor protein 63)
8ms
[VIRTUAL] TGF-β signaling pathway in salivary gland tumors (EACR 2021)
Comparing gene expression among SGTs types, we observed higher expression of SMAD4 in ACCs, as well as higher expression of ITGB6 and decreased expression of SMAD2 in MECs. Conclusion Altered expression of genes associated with TGF-β signaling may be involved in tumor progression and this knowledge is useful for the application of novel biological markers.
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • SMAD4 (SMAD family member 4) • TGFB1 (Transforming Growth Factor Beta 1) • LTBP1 (Latent-transforming growth factor beta-binding protein 1) • SMAD2 (SMAD Family Member 2)
|
MYC expression
8ms
[VIRTUAL] TGF-β signaling pathway in salivary gland tumors (EACR 2021)
Comparing gene expression among SGTs types, we observed higher expression of SMAD4 in ACCs, as well as higher expression of ITGB6 and decreased expression of SMAD2 in MECs. Conclusion Altered expression of genes associated with TGF-β signaling may be involved in tumor progression and this knowledge is useful for the application of novel biological markers.
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • SMAD4 (SMAD family member 4) • TGFB1 (Transforming Growth Factor Beta 1) • LTBP1 (Latent-transforming growth factor beta-binding protein 1) • SMAD2 (SMAD Family Member 2)
|
MYC expression
8ms
[VIRTUAL] TGF-β signaling pathway in salivary gland tumors (EACR 2021)
Comparing gene expression among SGTs types, we observed higher expression of SMAD4 in ACCs, as well as higher expression of ITGB6 and decreased expression of SMAD2 in MECs. Conclusion Altered expression of genes associated with TGF-β signaling may be involved in tumor progression and this knowledge is useful for the application of novel biological markers.
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • SMAD4 (SMAD family member 4) • TGFB1 (Transforming Growth Factor Beta 1) • LTBP1 (Latent-transforming growth factor beta-binding protein 1) • SMAD2 (SMAD Family Member 2)
|
MYC expression
8ms
[VIRTUAL] TGF-β signaling pathway in salivary gland tumors (EACR 2021)
Comparing gene expression among SGTs types, we observed higher expression of SMAD4 in ACCs, as well as higher expression of ITGB6 and decreased expression of SMAD2 in MECs. Conclusion Altered expression of genes associated with TGF-β signaling may be involved in tumor progression and this knowledge is useful for the application of novel biological markers.
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • SMAD4 (SMAD family member 4) • TGFB1 (Transforming Growth Factor Beta 1) • LTBP1 (Latent-transforming growth factor beta-binding protein 1) • SMAD2 (SMAD Family Member 2)
|
MYC expression
8ms
[VIRTUAL] Does the SWI/SNF chromatin remodeling complex play similar roles in various types of cancer? (EACR 2021)
Loss or overexpression of SWI/SNF results in tumor progression and chemoresistance dependent on tumor tissue origin and type: primary or metastatic. Financial support: Polpharma Scientific Foundation 5/XVII/18 (TJS)
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1
8ms
[VIRTUAL] Does the SWI/SNF chromatin remodeling complex play similar roles in various types of cancer? (EACR 2021)
Loss or overexpression of SWI/SNF results in tumor progression and chemoresistance dependent on tumor tissue origin and type: primary or metastatic. Financial support: Polpharma Scientific Foundation 5/XVII/18 (TJS)
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1
8ms
[VIRTUAL] Does the SWI/SNF chromatin remodeling complex play similar roles in various types of cancer? (EACR 2021)
Loss or overexpression of SWI/SNF results in tumor progression and chemoresistance dependent on tumor tissue origin and type: primary or metastatic. Financial support: Polpharma Scientific Foundation 5/XVII/18 (TJS)
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1
8ms
[VIRTUAL] Does the SWI/SNF chromatin remodeling complex play similar roles in various types of cancer? (EACR 2021)
Loss or overexpression of SWI/SNF results in tumor progression and chemoresistance dependent on tumor tissue origin and type: primary or metastatic. Financial support: Polpharma Scientific Foundation 5/XVII/18 (TJS)
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1
8ms
Clinical • New trial
|
CD24 (CD24 Molecule)
|
CD24 expression
8ms
Whole-genome Sequencing of Common Salivary Gland Carcinomas: Subtype Restricted and Shared Genetic Alterations. (PubMed, Clin Cancer Res)
This study delineates type-specific and shared genetic alterations that are associated with early phenotypic commitment and the biologic progression of common SGCs. These alterations, upon validation, could serve as biomarkers in tumor-specific clinical trials.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • BAP1 (BRCA1 Associated Protein 1) • CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
TP53 mutation • HER-2 amplification • HER-2 mutation • BAP1 mutation • CRTC1-MAML2 fusion
8ms
High-grade Transformation/Dedifferentiation in Salivary Gland Carcinomas: Occurrence Across Subtypes and Clinical Significance. (PubMed, Adv Anat Pathol)
HGT of salivary gland carcinoma can occur either at initial presentation or less commonly at the time of recurrence, sometimes following postoperative radiotherapy. The potential for HGT in almost any type of salivary gland carcinoma warrants a thorough sampling of all salivary gland malignancies to prevent oversight of a HG component.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 overexpression
8ms
New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • pemetrexed
8ms
A rare case of high-grade intraductal carcinoma of the upper lip: immunohistochemical and genetic analyses. (PubMed, Med Mol Morphol)
IDC of the minor salivary glands is exceedingly rare. We discuss diagnostic problems associated with minor salivary gland lesions, and the "basal-like" phenotype of this case.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • RET (Ret Proto-Oncogene) • AR (Androgen receptor) • NCOA4 (Nuclear Receptor Coactivator 4) • SOX10 (SRY-Box 10) • KRT19 (Keratin 19) • TP63 (Tumor protein 63)
|
RET fusion • NCOA4-RET fusion
8ms
High-grade Transformation/Dedifferentiation in Salivary Gland Carcinomas: Occurrence Across Subtypes and Clinical Significance. (PubMed, Adv Anat Pathol)
HGT of salivary gland carcinoma can occur either at initial presentation or less commonly at the time of recurrence, sometimes following postoperative radiotherapy. The potential for HGT in almost any type of salivary gland carcinoma warrants a thorough sampling of all salivary gland malignancies to prevent oversight of a HG component.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 overexpression
8ms
Intraductal Carcinoma of the Salivary Gland with NCOA4-RET: Expanding the Morphologic Spectrum and an Algorithmic Diagnostic Approach. (PubMed, Hum Pathol)
Typically regarded to have ETV6-NTRK3 fusions, secretory carcinomas may alternatively arise with RET fusions as well. Adding our cohort of 6 NCOA4-RET fusion-positive IC compared with 4 cases of secretory carcinoma with ETV6-RET fusions and a single case of fusion-negative IC with salivary duct carcinoma-like genetics, we propose a diagnostic algorithm that integrates histological elements, including atypia and invasiveness, and the likelihood of specific molecular alterations to increase diagnostic accuracy in what can be a very subtle diagnosis with important clinical implications.
Journal
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • NCOA4 (Nuclear Receptor Coactivator 4) • SOX10 (SRY-Box 10)
|
NTRK3 fusion • RET fusion • ETV6-NTRK3 fusion • RET rearrangement • NCOA4-RET fusion • RET positive
8ms
Updates in the molecular pathology of non-small cell lung cancer. (PubMed, Semin Diagn Pathol)
Finally, specific molecular pathological alterations define some rarer subtypes of NSCLC such as salivary gland tumours, NUT carcinoma and SMARCA4-deficient undifferentiated tumour, and an understanding of the molecular pathology is important for their accurate diagnosis. In this review, the molecular pathology of NSCLC is discussed with a focus on clinically relevant molecular alterations.
Review • Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • NTRK (Neurotrophic receptor tyrosine kinase)
|
EGFR mutation • BRAF mutation • ROS1 fusion • ALK-ROS1 fusion
8ms
Microsecretory Adenocarcinoma of Salivary Glands: An Expanded Series of 24 Cases. (PubMed, Head Neck Pathol)
MSA is a distinct salivary gland neoplasm with remarkably consistent clinical, histologic, immunophenotypic, and genetic features that generally behaves in an indolent manner following surgery alone. These observations solidify MSA as a unique, low-grade salivary gland carcinoma that warrants inclusion in the next version of the WHO classification of head and neck tumors.
Clinical • Journal
|
SOX10 (SRY-Box 10) • MEF2C (Myocyte Enhancer Factor 2C) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex) • TP63 (Tumor protein 63)
8ms
NISCAHN: Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck (clinicaltrials.gov)
P2, N=98, Active, not recruiting, UNICANCER | Trial completion date: Mar 2024 --> Oct 2021
Clinical • Trial completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
Opdivo (nivolumab)
8ms
Clinicopathological features and prognosis of nodal nevi (PubMed, Zhonghua Bing Li Xue Za Zhi)
The morphology of bland nevus cells in capsule and trabeculae is a valuable clue. Besides, immunohistochemical profiling and FISH assay are helpful in the differential diagnosis.
Clinical • Retrospective data • Journal
|
CDKN2A (Cyclin-dependent kinase inhibitor 2A) • SOX10 (SRY-Box 10)
8ms
NR4A3 (NOR-1) Immunostaining Shows Better Performance than DOG1 Immunostaining in Acinic Cell Carcinoma of Salivary Gland: a Preliminary Study. (PubMed, J Oral Maxillofac Res)
Moreover, only 3 (50%) cases showed complete membranous staining with DOG1. This pilot study showed that nuclear receptor subfamily 4 group A member 3 immunostaining is a sensitive marker for acinic cell carcinoma and of better utility than discovered on GIST-1 immunostaining in making a diagnosis of acinic cell carcinoma.
Journal
|
NR4A3 (Nuclear receptor subfamily 4 group A member 3)
9ms
Identification and characterization of primary cilia-positive salivary gland tumours exhibiting basaloid/myoepithelial differentiation. (PubMed, J Pathol)
Finally, we identified tau tubulin kinase 2 (TTBK2) as being possibly involved in the production of PC in SGTs. Taken together, our findings indicate that SGTs that exhibit basaloid/myoepithelial differentiation (PA, BCA, AdCC, and BCAc) are ciliated, and their PC exhibit tumour-specific characteristics, are involved in activation of the hedgehog pathway, and are associated with TTBK2 upregulation, providing a significant and important link between SGT tumourigenesis and PC.
Journal
|
GLI1 (GLI Family Zinc Finger 1)
|
GLI1 expression
9ms
Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response. (PubMed, Biomedicines)
On the contrary, a loss of Fas-expressing TIICs with increasing tumor stage was found in the tumor periphery, whereas FasL expression in tumor cells in the tumor periphery correlated with tumor stage. These data suggest that SGC cells are resistant to FasL-induced apoptosis by TIICs but could utilize FasL to eliminate these cells in high-stage tumors to provide resistance to immunotherapy.
Journal • IO biomarker
|
FAS (Fas cell surface death receptor) • FASLG (Fas ligand)
9ms
[VIRTUAL] NTRK, ALK and RET rearrangements in salivary gland cancer. (ASCO 2021)
ALK, NTRK, ROS1 and RET mutations define a new rare subtype of salivary gland adenocarcinomas with enormously poor prognosis . The presence ALK-mutation is an independent poor prognosis factorб negatively affecting both overall survival and progression-free survival . It’s advisable to consider the possibilities of using ALK, NTRK and RET inhibitors in this cohort of patients.
ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
|
ALK rearrangement • ALK fusion • RET mutation • ALK mutation • RET rearrangement • ROS1 fusion • ALK-ROS1 fusion • RET expression • NTRK expression • NTRK fusion
9ms
DUET-2: A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (clinicaltrials.gov)
P1, N=154, Recruiting, Xencor, Inc. | Trial completion date: Mar 2021 --> Feb 2023 | Trial primary completion date: Dec 2020 --> Feb 2022
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MSI (Microsatellite instability)
|
MSI-H/dMMR • HER-2 negative
|
vudalimab (XmAb717)
9ms
[VIRTUAL] Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials. (ASCO 2021)
ARX788 demonstrated promising activity in HER2-positive, HER2-low, and T-DM1 resistant tumors in preclinical studies . High stability of ARX788 and low serum exposure of pAF-AS269 may underlie the low systemic toxicity, which differentiates it from other ADCs.
Clinical • P1 data • PK/PD data
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Kadcyla (ado-trastuzumab emtansine) • ARX788
9ms
Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors. (PubMed, Am J Surg Pathol)
The lack of pan-TRK immunoreactivity in a subset of SCs is suggestive of atypical exons 4 to 14 or exons 5 to 14 ETV6-NTRK3 fusion or non-NTRK alternative fusion partners such as ETV6-RET. Pan-TRK staining can serve as a strong diagnostic marker to distinguish SC from it mimics and to select patients eligible for TRK inhibitor clinical trials.
Journal
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK3 fusion • RET fusion • ETV6-NTRK3 fusion
9ms
[VIRTUAL] Heterozygous ATM Mutation Associated with Immunodeficiency and Recurrent Malignancy (CIS 2021)
He subsequently developed a diffuse large B-cell lymphoma in the retroperitoneum two years later, which was successfully treated with R-CHOP...Whole exome sequencing was obtained because of the patient's history of unusual and recurrent malignancy in association with immunodeficiency identifying a heterozygous pathogenic mutation in ATM (c.2098 C>T, p.Q700X). Heterozygous ATM mutations may cause an ATM-related disorder manifesting with immunodeficiency and predisposition to malignancy without neurodegeneration.
ATM (ATM serine/threonine kinase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
ATM mutation
|
Rituxan (rituximab)
9ms
Utility of an immunocytochemical analysis for pan-Trk in the cytodiagnosis of secretory carcinoma of the salivary gland. (PubMed, Diagn Cytopathol)
The immunocytochemical analyses clearly demonstrated that all eight specimens showed positive nuclear staining for pan-Trk, but were negative for NR4A3 expression. Although all cases of SC do not always show positive immunoreactivity for pan-Trk, immunocytochemical analysis for pan-Trk may be useful for the cytodiagnosis of SC along with assessment of the characteristic cytological features.
Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • NR4A3 (Nuclear receptor subfamily 4 group A member 3)
|
NTRK3 fusion • ETV6-NTRK3 fusion
9ms
Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target. (PubMed, Head Neck Pathol)
This is the first study to demonstrate that several types of SGC express Trop-2 with variable intensity. Since there are currently few systemic treatment options for advanced SGCs, Trop-2 represents a promising target for further clinical studies, for instance, with sacituzumab govitecan.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2)
|
Trodelvy (sacituzumab govitecan-hziy)
9ms
YATAGARASU: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (clinicaltrials.gov)
P2, N=31, Active, not recruiting, Janssen Pharmaceutical K.K. | Trial primary completion date: Mar 2021 --> Jun 2021
Clinical • Trial primary completion date • Combination therapy
|
AR (Androgen receptor)
|
AR positive • AR expression
|
Erleada (apalutamide) • goserelin acetate
9ms
SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets. (PubMed, Neoplasia)
Further, a rare case of a SS18-ZBTB7A rearranged low-grade adenocarcinoma previously described as potential spectrum of microsecretory adenocarcinoma, is reported. In addition, features of six cases within the spectrum of polymorphous adenocarcinoma / cribriform adenocarcinoma of salivary gland including PRKD1 p.E710D mutations and novel fusions involving PRKAR2A-PRKD1, SNX9-PRKD1 and ATL2-PRKD3, are described.
Journal • Next-generation sequencing
|
RET (Ret Proto-Oncogene) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NR4A3 (Nuclear receptor subfamily 4 group A member 3) • NFIB (Nuclear Factor I B) • NTRK (Neurotrophic receptor tyrosine kinase) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex) • ZBTB7A (Zinc finger and BTB domain containing 7A) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
NTRK2 fusion • RET fusion • MYB-NFIB fusion
9ms
The spectrum of tumors harboring BAP1 gene alterations. (PubMed, Cancer Genet)
More same tissue tumors of squamous cell histology harbored BAP1 alterations than adenocarcinomas. The current study highlights tumor types that display higher than previously appreciated rates of somatic BAP1 genomic alterations.
Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BAP1 (BRCA1 Associated Protein 1)
|
BRCA1 mutation • BAP1 mutation
9ms
ALK Rearrangements Characterize 2 Distinct Types of Salivary Gland Carcinomas: Clinicopathologic and Molecular Analysis of 4 Cases and Literature Review. (PubMed, Am J Surg Pathol)
Given the therapeutic relevance of ALK fusions, inclusion of ALK IHC in any atypical-looking or androgen-poor SDC and in high-grade adenocarcinoma-not otherwise specified is recommended. Absence of aberrant ALK expression in genetically characterized secretory (n=15) and intraductal (n=9) carcinomas lacking ALK fusions underlines the value of ALK IHC as a diagnostic screening method for identifying potential cases.
Clinical • Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • AR (Androgen receptor) • STRN (Striatin) • NKX2-1 (NK2 Homeobox 1) • SOX10 (SRY-Box 10) • MUC4 (Mucin 4, Cell Surface Associated) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • NAPSA (Napsin A Aspartic Peptidase)
|
ALK positive • HER-2 expression • ALK rearrangement • ALK fusion • AR expression
9ms
The potential of somatostatin receptor 2 as a novel therapeutic target in salivary gland malignant tumors. (PubMed, J Cancer Res Clin Oncol)
This study confirms the expression of SSTR2 in glandular salivary carcinomas and an inverse correlation in expression levels between SSTR2 and Ki-67. This lays a foundation for novel treatment options in salivary metastatic cancers where SSTR2 may be a potential novel therapeutic target.
Retrospective data • Journal
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
9ms
Immunohistochemical Expression of Fatty Acid Synthase (FASN) is Correlated to Tumor Aggressiveness and Cellular Differentiation in Salivary Gland Carcinomas. (PubMed, Head Neck Pathol)
Also, FASN expression was significantly higher in high-grade AdCC and MEC when compared to low-grade tumors (p < 0.05). We concluded that FASN expression was correlated to tumor aggressiveness and cellular differentiation in salivary gland carcinomas.
Journal
|
FAS (Fas cell surface death receptor) • FASN (Fatty acid synthase)
9ms
Integrative sequencing discovers an ATF1-motif enriched molecular signature that differentiates hyalinizing clear cell carcinoma from mucoepidemoid carcinoma. (PubMed, Oral Oncol)
Collectively, our data identify an ATF1-motif enriched gene signature that may have clinical utility for molecular differentiation of HCCCs from other salivary gland tumors and discover potential actionable alterations that may benefit the clinical care of recurrent HCCC patients.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • IGF1R (Insulin-like growth factor 1 receptor) • EWSR1 (EWS RNA Binding Protein 1) • IGF2 (Insulin-like growth factor 2) • ATF1 (Activating Transcription Factor 1)
|
IGF1R expression • IGF1 elevation
9ms
Acinic Cell Carcinoma of the Breast: Report of a Case With Immunohistochemical and Next-Generation Sequencing Studies. (PubMed, Int J Surg Pathol)
She was treated with neoadjuvant therapy (doxorubucin and cyclophosphamide) antenatally and paclitaxel in the postpartum period followed by left mastectomy with sentinel node biopsy...We retrospectively performed immunostains in the core biopsy specimen, which demonstrated GATA-3 and DOG-1 positivity. Next-generation sequencing of the postneoadjuvant specimen using a 70-gene panel revealed 2 single-nucleotide variant (SNV) mutations: tumor protein 53 (TP53) (c.747G>T) SNV mutation and rearranged during transfection (RET) (c.2899G>A) SNV mutation.
Clinical • Journal • Next-generation sequencing
|
TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • GATA3 (GATA binding protein 3)
|
TP53 mutation
|
paclitaxel
9ms
The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma. (PubMed, JCI Insight)
Here, we show that doxycycline-induced CRTC1-MAML2 knockdown blocked the growth of established MEC xenografts, validating CRTC1-MAML2 as a therapeutic target. Cotargeting of aberrant p16-CDK4/6-RB signaling and CRTC1-MAML2 fusion-activated AREG/EGFR signaling with the respective CDK4/6 inhibitor Palbociclib and EGFR inhibitor Erlotinib produced enhanced antitumor responses in vitro and in vivo. Collectively, this study provides direct evidence for CRTC1-MAML2 as a key driver for MEC development and maintenance and identifies a potentially novel combination therapy with FDA-approved EGFR and CDK4/6 inhibitors as a potential viable strategy for patients with MEC.
Journal
|
CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
|
CRTC1-MAML2 fusion
|
erlotinib • Ibrance (palbociclib) • doxycycline
10ms
Sclerosing mucoepidermoid carcinoma of the salivary glands: report of three cases with special concern to the counterpart accompanied by eosinophilia. (PubMed, Med Mol Morphol)
The two SMCEs included dense aggregates of eosinophils as well as more prominent lymphoid infiltration. Fluorescence in situ hybridization for MAML2 confirmed split signals in SMC, but not in SMCE.
Clinical • Journal
|
MAML2 (Mastermind Like Transcriptional Coactivator 2)
10ms
Mast Cells and Proteins Related to Myofibroblast Differentiation (PAR-2, IL-6, and TGFβ1) in Salivary Cancers: A Preliminary Study. (PubMed, Appl Immunohistochem Mol Morphol)
When the density of mast cells, myofibroblasts and the expression of PAR-2 protein, IL-6, and TGFβ1 were compared, it was no statistically significant difference between tumors with and without myoepithelial differentiation. The results of present study suggest a possible participation of mast cells and especially of PAR-2 in the development and progression of malignant salivary cancers, regardless of myoepithelial content.
Journal
|
IL6 (Interleukin 6) • TGFB1 (Transforming Growth Factor Beta 1)
10ms
Clinical Significance of Histone Deacetylase (HDAC)-1, -2, -4 and -6 Expression in Salivary Gland Tumors. (PubMed, Diagnostics (Basel))
Additionally, a high HDAC-2 H-score was significantly associated with longer OS for HG malignant SGT patients (p = 0.027). In our study, HDAC-2 expression is a marker for good prognosis, whereas HDAC-6 expression indicated poor prognosis; thus, an inhibitor of HDAC-6 may be used to improve patients' survival.
Clinical • Journal • Epigenetic controller
|
HDAC2 (Histone deacetylase 2)
|
HDAC2 expression
10ms
Genetic Drivers of Head and Neck Squamous Cell Carcinoma: Aberrant Splicing Events, Mutational Burden, HPV Infection and Future Targets. (PubMed, Genes (Basel))
This review aims to describe changes in alternative splicing and ncRNA patterns that contribute to the development and progression of HNSCC. It will also review the use of the changes in gene expression as biomarkers or as the basis for the development of new therapies.
Review • Journal • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden)
10ms
The immunophenotype of epithelial to mesenchymal transition inducing transcription factors in salivary gland adenoid cystic carcinomas. (PubMed, Rom J Morphol Embryol)
Thus, tumors developed from the intraoral minor salivary glands, with solid pattern, perineural invasion, locally aggressive and with lymph node metastasis were the most reactive. Therefore, these transcription factors could be useful as prognostic biomarkers and efficient therapeutic targets in such salivary malignancies.
Journal
|
ZEB1 (Zinc Finger E-box Binding Homeobox 1)
10ms
Clinical • New P2 trial
|
BCL2 (B-cell CLL/lymphoma 2)
|
carboplatin • elraglusib (9-ING-41)
10ms
Secretory carcinoma ex pleomorphic adenoma of the submandibular gland: An immunohistochemical study. (PubMed, Oral Oncol)
The myoepithelial markers showed positivity for residual cellsin hyalinized area, corresponding to residual Pleomorphic adenoma (PA). In view of these findings, the diagnosis of Secretory carcinoma ex pleomorphic adenoma (SCXPA) was established.
Journal
|
PLIN2 (Perilipin)
10ms
Clinicopathological and immunohistochemical behavior of ductal carcinoma of the salivary and lacrimal gland in a Mexican Mestizo population. (PubMed, Eur Arch Otorhinolaryngol)
SDC is a rare entity and survival is very poor. It is histologically similar to ductal carcinoma of the breast. However, important differences exist that help to distinguish them in case of synchronous cancers. The clinical behavior of SDC seems to be more aggressive and IHC analysis is useful for designing therapies.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor) • SOX10 (SRY-Box 10) • PAX8 (Paired box 8) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
10ms
Assessment Of Tumour Infiltrating Lymphocytes And Pd-l1 Expression In Adenoid Cystic Carcinoma Of The Salivary Gland. (PubMed, Clin Invest Med)
There was no association between TIL expression and survival. These data suggest that PD-L1 and TIL expression are unlikely to be useful as predictive biomarkers for response to immunotherapy.
Journal • Tumor-Infiltrating Lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • PD-L1 negative
10ms
Recent updates in salivary gland tumors of the lung. (PubMed, Semin Diagn Pathol)
Awareness of these tumors and knowledge of available ancillary studies to confirm the diagnosis is important to avoid misdiagnosis which might lead to differences in treatment, management, and prognosis. Further studies are needed to identify biomarkers to better predict patient's outcome and for individual management and treatment of patients.
Journal
|
EWSR1 (EWS RNA Binding Protein 1)
10ms
Clinical • Enrollment change • Pan tumor
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK rearrangement • ROS1 rearrangement
|
Xalkori (crizotinib) • Rozlytrek (entrectinib)
10ms
Sialadenoma papilliferum: clinicopathologic, Immunohistochemical, molecular analyses of new five cases and review of the literature. (PubMed, Diagn Pathol)
For the first time, we have comprehensively aggregated and analyzed 90 cases sialadenoma papilliferum from almost all previous publications, and further explored the clinicopathological features of SP; concordantly, this study demonstrated that SP shows a papillomatous growth pattern with exophytic and endophytic proliferation of ductal epithelium composed of double-layered cells harboring BRAF V600E mutation. Additionly, adequate treatment for SP is surgical excision, with a favorable prognosis in patients.
Clinical • Review • Journal
|
BRAF (B-raf proto-oncogene) • TP63 (Tumor protein 63)
|
BRAF V600E • BRAF V600
10ms
[VIRTUAL] Establishment of clinically and genetically well-annotated patient-derived xenografts of adenoid cystic carcinoma with high-grade transformation (AACR 2021)
Further, chemotherapy (carboplatin/paclitaxel) was conducted on the PDX model. All three PDX models had histopathological features similar to those of the original tumors, and retained the MYB-NFIB fusion gene. We successfully established PDX models of adenoid cystic carcinoma, including an HGT model, which was characterized by detailed clinical and genomic information. Tumors that show HGT characteristics may be drug-sensitive, and can be used in the development of personalized cancer treatments.
Clinical
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • SOX10 (SRY-Box 10) • NFIB (Nuclear Factor I B) • TP63 (Tumor protein 63)
|
MYB-NFIB fusion
|
carboplatin • paclitaxel
10ms
[VIRTUAL] Patient-derived models of rare cancers in the National Cancer Institute’s patient-derived models repository (AACR 2021)
Also of clinical relevance, of two mesothelioma models available, one carries an NF2 driver mutation and the other BAP1 and LATS2 and a PDX model for Hurthle cell carcinoma has wide-spread loss of heterozygosity (LOH 80%). Models for other rare cancers are in development, including four cholangiocarcinoma PDXs with histopathologic confirmation that are currently being expanded for molecular characterization and distribution.
Clinical
|
CDKN2A (Cyclin-dependent kinase inhibitor 2A) • NF1 (Neurofibromin 1) • BAP1 (BRCA1 Associated Protein 1) • EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • STAT6 (Signal transducer and activator of transcription 6)
|
CDKN2A deletion • NF1 mutation • BAP1 mutation • EWSR1-FLI1 fusion
10ms
BOC-PLAG1, a new fusion gene of pleomorphic adenoma: Identified in a fine-needle aspirate by RNA next-generation sequencing. (PubMed, Diagn Cytopathol)
To our knowledge, this is the first reported PA bearing BOC-PLAG1. RNA next-generation sequencing performed on cytology specimens can be helpful in achieving a more specific diagnosis of salivary gland tumors.
Journal • Next-generation sequencing
|
HMGA2 (High mobility group AT-hook 2)
10ms
Cabo ASAP: Cabozantinib in Advanced Salivary Gland Cancer Patients (clinicaltrials.gov)
P2, N=25, Terminated, Radboud University | Active, not recruiting --> Terminated; safety issues
Clinical • Trial termination
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET positive
|
Cabometyx (cabozantinib tablet)
10ms
[VIRTUAL] Nursing Consideration in Salivary Gland Cancer (SGC) Patients Receiving Targeted Therapy in the new era of Molecular Profiling: What is the Current Update? (ONS 2021)
Patients with advanced SGC can participate in several clinical trials studying various targeted agents such as pertuzumab and trastuzumab with HER2 alteration, vismodegib with PTCH-1/SMO mutation, vemurafenib with BRAF V600 mutation, or atezolizumab with high tumor mutational burden (TMB). Discussion & Innovation: Oncology nurses need to be cognizant of currently studied targeted agents used to treat SGC patients. As an increased number of patients are receiving novel targeted agent treatment, oncology nurses need to engage in collaborative groups to educate and improve management of adverse events.
Clinical • Tumor Mutational Burden • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • PTCH1 (Patched 1) • SMO (Smoothened Frizzled Class Receptor)
|
TMB-H • BRAF mutation • BRAF V600 • HER-2 mutation • PTCH1 mutation
|
Herceptin (trastuzumab) • Zelboraf (vemurafenib) • Tecentriq (atezolizumab) • Perjeta (pertuzumab) • Erivedge (vismodegib)
11ms
Secretory Carcinoma of the Oral Cavity: A Retrospective Case Series with Review of Literature. (PubMed, Head Neck Pathol)
A judicious application of IHC staining would aid in diagnosis. SC should be considered in the differential diagnosis for intraoral salivary gland tumors.
Retrospective data • Review • Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • SOX10 (SRY-Box 10) • GATA3 (GATA binding protein 3)
|
NTRK3 fusion • ETV6-NTRK3 fusion
11ms
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (clinicaltrials.gov)
P1, N=15, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
CD4 (CD4 Molecule)
|
HER-2 positive • HER-2 amplification • HER-2 expression
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)
11ms
Prognostic value of the immunohistochemical expression of vascular endothelial growth factors in malignant salivary gland neoplasms: a systematic review and meta-analysis. (PubMed, Med Oral Patol Oral Cir Bucal)
The immunohistochemical overexpression of vascular endothelial growth factor in patients with salivary gland neoplasms has prognostic value and was associated with decreased survival time. However, more primary well-designed studies are necessary to increase the level of evidence.
Retrospective data • Review • Journal
|
VEGFA (Vascular endothelial growth factor A)
|
VEGFA expression
11ms
The potential role of follicular helper T cells and helper T cells type 1 in Warthin tumour. (PubMed, Pathol Res Pract)
We observed that Tfh were involved in the formation and maintenance of lymphoid follicles in WTs. In the cyst-type, Th2-dominant humoral immune responses were suppressed, and Th1-dominant cellular immune responses may have caused damage to tumour tissue.
Journal • IO biomarker
|
CD40LG (CD40 ligand)
11ms
CRTC1/MAML2 directs a PGC-1α-IGF-1 circuit that confers vulnerability to PPARγ inhibition. (PubMed, Cell Rep)
Furthermore, this dependence on autocrine regulation of IGF-1 transcription renders MEC cells susceptible to PPARγ inhibition with inverse agonists. These results yield insights into the aberrant coregulatory functions of C1/M2 and identify a specific vulnerability that can be exploited for precision therapy.
Journal
|
IGF1 (Insulin-like growth factor 1)
11ms
Clinical • Enrollment change • Combination therapy
|
CD4 (CD4 Molecule)
|
HER-2 positive • HER-2 amplification • HER-2 expression
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)
11ms
Clear Cell Odontogenic Carcinoma: First Report of Novel EWSR1-CREM Fusion Gene in Case of Long-Term Misdiagnosis. (PubMed, Head Neck Pathol)
CREM fusion proteins have only recently been found in several tumour types including the closely associated hyalinizing clear cell carcinoma of salivary glands. This is discussed in this paper, and the role of the discovery of the CREM fusion protein in CCOC adds to your understating of the role of CREM in oncogenesis, and the possible link between CCOCs and hyalinizing clear cell carcinomas.
Clinical • Journal
|
EWSR1 (EWS RNA Binding Protein 1) • ATF1 (Activating Transcription Factor 1) • CREB1 (CAMP Responsive Element Binding Protein 1)
|
EWSR1-CREB1 fusion
11ms
Initial cytodiagnosis of salivary gland tumor on liver fine needle aspirate. (PubMed, Cytopathology)
Chest roentgenogram was normal. Contrast enhanced MRI scan of the abdomen revealed large, relatively well defined, heterogeneously enhancing space occupying lesion measuring 11.5x19.7x14.5 cm with multiple smaller nodules scattered all over the liver, suggestive of hemangioendothelioma or metastasis.
Journal
|
Cancer antigen 19-9
11ms
[VIRTUAL] Nuclear Expression of NR4A3 by Immunohistochemistry Distinguishes Acinic Cell Carcinoma from its Mimics on Fine-Needle Aspiration Samples (USCAP 2021)
Our data demonstrate that nuclear expression of NR4A3 by IHC is highly sensitive and specific for AciCC, and distinguishes AciCC from its mimics; therefore, NR4A3 by IHC can be utilized in cytology FNA samples where the diagnosis of AciCC is considered. Additional large series of study may be necessary to validate our findings.
NR4A3 (Nuclear receptor subfamily 4 group A member 3)
11ms
[VIRTUAL] Glial Fibrillary Acidic Protein Expression Helps Distinguish Pleomorphic Adenoma from Malignant Biphasic Tumours of the Salivary Glands (USCAP 2021)
Almost all PAs show strong expression of GFAP. In contrast, most malignant neoplasms that can mimic PA on small biopsies show only rare expression. Other benign tumours composed of abluminal cells also show strong expression of GFAP highlighting the spectrum these tumours share with PA.
GFAP (Glial Fibrillary Acidic Protein)
11ms
[VIRTUAL] MYB Expression by RNA In-Situ Hybridization is Sensitive and Specific for Adenoid Cystic Carcinoma (USCAP 2021)
Our data suggest that MYB expression by RNA ISH is sensitive and specific for AdCC, with an overall sensitivity of 87% and specificity of 91%. MYB RNA ISH assay can be applied in assisting the diagnosis of AdCC on cytology FNA samples. The significance of lower sensitivity in AdCCs from trachea and lung is uncertain, requiring future large series of studies to validate or explore further of our findings
MYB (MYB Proto-Oncogene, Transcription Factor) • NFIB (Nuclear Factor I B)
|
MYB-NFIB fusion
11ms
[VIRTUAL] Acinic Cell Carcinoma: NR4A3 Fluorescence In Situ Hybridization Analysis in 40 Cytologic and Surgically Resected Specimens (USCAP 2021)
NR4A3 FISH has a sensitivity of 58% and specificity of 100% in detecting ACC which suggests that NR4A3 rearrangement-driven upregulation is a recurrent, specific oncogenic event in ACC, consistent with prior results. 100% concordance between matched resections/FNAs validates its potential utility on cytology samples. FISH (+) ACC had no specific morphologic correlates.
NR4A3 (Nuclear receptor subfamily 4 group A member 3)
11ms
[VIRTUAL] Immunohistochemical Detection of pan-Tropomyosin Receptor Kinase (pan-TRK) Expression in Solid Tumor Specimens: Inter-Laboratory and Inter-Reader Agreement in NGS-confirmed NTRK Fusion-Positive and Fusion-Negative Cases (USCAP 2021)
This study provides a framework to assess the inter-reader agreement of the automated VENTANA pan-TRK (EPR17341) Assay in NGS-confirmed NTRK gene fusion-positive and fusion-negative cases. Overall agreement between readers was high, but varied based on fusion partner and staining pattern observed with this analytic assay.
Clinical • Next-generation sequencing
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • EML4 (EMAP Like 4) • ETV6 (ETS Variant Transcription Factor 6) • TPM3 (Tropomyosin 3) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ETV6-NTRK3 fusion • NTRK fusion • NTRK positive
|
VENTANA pan-TRK (EPR17341) Assay
11ms
[VIRTUAL] NOR-1 (NR4A3) Immunostaining Can Be Reliably Performed on Cytologic Preparations for the Preoperative Diagnosis of Acinic Cell Carcinoma of the Salivary Gland (USCAP 2021)
NOR-1 immunohistochemical staining can be reliably performed on cytologic smears and liquid-based preparations of salivary gland tumors. This provides a valuable tool for distinguishing ACC-SG from its cytologic mimics on preoperative cytology with excellent sensitivity and specificity to optimize patient management.
NR4A3 (Nuclear receptor subfamily 4 group A member 3)
11ms
Clinical
|
NR4A3 (Nuclear receptor subfamily 4 group A member 3)
11ms
Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma. (PubMed, Oral Oncol)
MEC cells are intrinsically tolerant to EGFR inhibition. Combining EGFR and HDAC inhibitors exerts synergistic and potent cytotoxic effects, suggesting that EGFR inhibitors still hold significant promise against MEC. Future studies are needed to assess the applicability and efficacy of dual EGFR-HDAC inhibitors for the clinical management of MEC.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor)
|
erlotinib • Zolinza (vorinostat) • CUDC-101
11ms
Secretory carcinoma of salivary glands at the National Cancer Institute: A 20-year retrospective clinical, pathological, immunohistochemical and molecular study. (PubMed, Oral Oncol)
The present study adds seven cases of secretory carcinoma to the literature, contributing to a better understanding of the epidemiological, histological, immunohistochemical and molecular characteristics of this recently described tumor. Also, the use of a comprehensive diagnostic approach, including immunohistochemical and molecular methods, along with classical morphological studies, allowed the reclassification of acinic cell carcinoma to secretory carcinoma.
Retrospective data • Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
11ms
The tumor immune contexture of salivary duct carcinoma. (PubMed, Head Neck)
In this small series of SDC, biomarkers do not seem to correlate with disease biology, although they provide additional treatment options. SDC may harbor a different immune profile compared to other subtypes, with an indication of T-cell dysfunction.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3)
|
PD-L1 expression • HER-2 amplification • HER-2 overexpression • AR splice variant 7 • HER-2 amplification + PD-L1 expression
11ms
Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma. (PubMed, Oral Oncol)
Due to disappointing results with chemotherapy, new approaches are under study, also on the basis of biomolecular research. Ongoing clinical trials are evaluating treatment targeting MYB and NOTCH1 alterations, immunotherapy or combination of targeted treatments and immune checkpoint inhibitors.
Review • Journal • IO biomarker
|
TP53 (Tumor protein P53) • NOTCH1 (Notch 1)
|
TP53 mutation • NOTCH1 mutation
11ms
Differential bioinformational model for diagnostics of inflammatory and tumor diseases of the parotid salivary gland (PubMed, Stomatologiia (Mosk))
Comparison of the concentration of IL-6 and IL-10 in saliva and their ratio defined by the developed discriminant models helps to make an individual diagnostic decision in a specific clinical situation.
Journal
|
IL6 (Interleukin 6) • IL10 (Interleukin 10)
11ms
Diagnosis and therapy of tumors with NTRK gene fusion (PubMed, Pathologe)
If NTRK gene fusions are detected, TRK inhibitors such as entrectinib and larotrectinib can be used regardless of the tumor entity. On one hand, patients with NTRK gene fusions should be identified; on the other hand, epidemiological, histological, and resource-related aspects have to be taken into account. Based on these premises, we suggest a diagnostic algorithm for TRK fusion cancers and present current data on TRK inhibitors.
Review • Journal
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
|
Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)
11ms
Primary Large Cell Neuroendocrine Carcinoma of the Parotid Gland. Report of a Rare Case. (PubMed, Head Neck Pathol)
It is concluded that primary LCNEC of the salivary glands presents as a high-grade undifferentiated carcinoma, whose diagnosis may be hindered by its rarity and non-specific light microscopic features. A high level of awareness, immunohistochemical staining for neuroendocrine markers synaptophysin and CD56, and a thorough diagnostic work-up in order to exclude metastasis from a primary neuroendocrine carcinoma will allow its diagnosis.
Clinical • Journal
|
NCAM1 (Neural cell adhesion molecule 1)
11ms
Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK3 fusion • ETV6-NTRK3 fusion
12ms
Salivary Duct Carcinoma With Rhabdoid Features-No or Aberrant Expression of E-cadherin and Genetic Changes in CDH1: Immunohistochemical and Genetic Analyses of 17 Cases. (PubMed, Am J Surg Pathol)
Among the 11 cases that could be genetically analyzed, a nonsense mutation (1 case), missense mutations (6 cases), and insertions (1 case) were detected in the CDH1 gene. In conclusion, we propose that SDCRF is the salivary counterpart of PLCB due to its morphology and immunophenotype, and the genetic status of CDH1.
Clinical • Journal
|
AR (Androgen receptor) • CDH1 (Cadherin 1) • VIM (Vimentin) • SMARCD3 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily D, Member 3)
|
CDH1 expression • VIM expression
12ms
[VIRTUAL] SECONDARY MALIGNANCIES AFTER ALLOGENEIC HSCT IN CHILDREN (EBMT 2021)
 Secondary malignancies in children after HSCT develop predominantly in patients with genomic instability or chronic GVHD, have poor treatment response and lead to decrease of survival. Less GVHD incidence after T-cell depletion in Group 2 and shorter follow-up period could explain lower rate of secondary neoplasms. High risk patients should be closely monitored for early detection and prompt treatment.
Clinical
|
CD19 (CD19 Molecule) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TCL1A (TCL1 Family AKT Coactivator A)
12ms
[VIRTUAL] SECONDARY MALIGNANCIES AFTER ALLOGENEIC HSCT IN CHILDREN (EBMT 2021)
 Secondary malignancies in children after HSCT develop predominantly in patients with genomic instability or chronic GVHD, have poor treatment response and lead to decrease of survival. Less GVHD incidence after T-cell depletion in Group 2 and shorter follow-up period could explain lower rate of secondary neoplasms. High risk patients should be closely monitored for early detection and prompt treatment.
Clinical
|
CD19 (CD19 Molecule) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TCL1A (TCL1 Family AKT Coactivator A)
12ms
[VIRTUAL] SECONDARY MALIGNANCIES AFTER ALLOGENEIC HSCT IN CHILDREN (EBMT 2021)
 Secondary malignancies in children after HSCT develop predominantly in patients with genomic instability or chronic GVHD, have poor treatment response and lead to decrease of survival. Less GVHD incidence after T-cell depletion in Group 2 and shorter follow-up period could explain lower rate of secondary neoplasms. High risk patients should be closely monitored for early detection and prompt treatment.
Clinical
|
CD19 (CD19 Molecule) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TCL1A (TCL1 Family AKT Coactivator A)
12ms
[VIRTUAL] SECONDARY MALIGNANCIES AFTER ALLOGENEIC HSCT IN CHILDREN (EBMT 2021)
 Secondary malignancies in children after HSCT develop predominantly in patients with genomic instability or chronic GVHD, have poor treatment response and lead to decrease of survival. Less GVHD incidence after T-cell depletion in Group 2 and shorter follow-up period could explain lower rate of secondary neoplasms. High risk patients should be closely monitored for early detection and prompt treatment.
Clinical
|
CD19 (CD19 Molecule) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TCL1A (TCL1 Family AKT Coactivator A)
12ms
A Distinctive Adnexal (Usually Paratubal) Neoplasm Often Associated With Peutz-Jeghers Syndrome and Characterized by STK11 Alterations (STK11 Adnexal Tumor): A Report of 22 Cases. (PubMed, Am J Surg Pathol)
Wolffian, sex cord stromal, epithelial, and mesothelial origins were considered. We propose the term STK11 adnexal tumor to describe this novel entity and emphasize the importance of genetic counseling in these patients as a significant number of neoplasms occur in association with Peutz-Jeghers syndrome.
Clinical • Journal
|
STK11 (Serine/threonine kinase 11) • WT1 (WT1 Transcription Factor) • NKX2-1 (NK2 Homeobox 1) • PAX8 (Paired box 8) • GATA3 (GATA binding protein 3)
12ms
DNA base excision repair and nucleotide excision repair proteins in malignant salivary gland tumors. (PubMed, Arch Oral Biol)
This study showed that BER and NER proteins evaluated are highly expressed in the MSGTs studied, indicating mechanisms of genotoxic control in these tumors. In addition, the dysregulation of XRCC1 expression was a prognostic predictor in MSGTs analyzed.
Journal
|
RAD23B (RAD23 Homolog B) • XRCC1 (X-Ray Repair Cross Complementing 1)
12ms
Sialadenoma Papilliferum. (PubMed, Surg Pathol Clin)
Conservative surgical treatment seems to be adequate with a low recurrence. SOX10 immunohistochemistry and BRAF analysis may be useful in differential diagnosis.
Review • Journal
|
BRAF (B-raf proto-oncogene) • HRAS (Harvey rat sarcoma viral oncogene homolog) • SOX10 (SRY-Box 10)
|
BRAF V600E • BRAF V600 • HRAS mutation
12ms
Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers. (PubMed, Surg Pathol Clin)
Genomic abnormalities have led to the emergence of targeted therapies being used in their therapy with drastic improvements in outcomes as well as reductions in treatment-related toxicity. Dramatic results seen with molecular targets, such as HER2, TRK, and others, indicate that this approach has the potential to yield even better treatments for the future.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
12ms
Salivary Duct Carcinoma: An Aggressive Salivary Gland Carcinoma with Morphologic Variants, Newly Identified Molecular Characteristics, and Emerging Treatment Modalities. (PubMed, Surg Pathol Clin)
For SDC, current treatment strategies are aggressive and commonly include surgical excision with lymph node dissection and adjuvant radiotherapy. Continued research is examining the utility of androgen deprivation therapy and targeted molecular therapy.
Review • Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
AR positive • ER negative • PGR negative
12ms
Epithelial-Myoepithelial Carcinoma. (PubMed, Surg Pathol Clin)
Because clear myoepithelial cells are also noted in other benign and malignant salivary gland tumors, the histologic variety and similarity with other tumor entities make the diagnosis of epithelial-myoepithelial carcinoma challenging. A recent analysis revealed that HRAS hotspot point mutations are specifically identified in epithelial-myoepithelial carcinoma and the assessment of given genes facilitate the correct diagnosis.
Review • Journal
|
HRAS (Harvey rat sarcoma viral oncogene homolog)
|
HRAS mutation
12ms
The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay. (PubMed, Biomedicines)
PD-1-positive tumor cells were detected exclusively in the tumor center of high-grade tumors, and most importantly, the presence of lymph node (LN) metastases and primary tumor stage significantly correlated with the presence of PD-L1-positive tumor cells in the tumor periphery. The PD-1/PD-L1 molecular signatures in SGC are clustered predominantly in the tumor periphery, reflect disease severity, and may predict the response to ICI immunotherapy in SGC patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 overexpression • PD-1 expression
12ms
Low-Grade Intraductal Carcinoma of the Parotid Gland: A Case Report and Literature Review. (PubMed, Head Neck Pathol)
Their main histopathological features are reported in the paper. Here we present a case report and a review of scientific literature on this topic to provide some essential diagnostic tools to discriminate this rare entity.
Clinical • Review • Journal
|
SOX10 (SRY-Box 10) • TP63 (Tumor protein 63)
12ms
p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. (PubMed, Biomark Res)
The high prevalence of p63 expression in specific tumor types makes p63 immunohistochemistry a suitable diagnostic tool. Loss of p63 expression might constitute a feature of aggressive cancers.
Journal
|
TP63 (Tumor protein 63)
12ms
Survival of salivary gland cancer stem cells requires mTOR signaling. (PubMed, Cell Death Dis)
Using a panel of inhibitors of the mTOR pathway, i.e., rapamycin and temsirolimus (mTOR inhibitors), buparlisib and LY294002 (AKT inhibitors), and PF4708671 (S6K1 inhibitor), we observed consistently dose-dependent decrease in the fraction of CSC, as well as inhibition of secondary sphere formation and self-renewal in three human MEC cell lines (UM-HMC-1,-3A,-3B)...In contrast, conventional chemotherapeutic drugs (cisplatin, paclitaxel) induced preferential apoptosis of bulk tumor cells and accumulation of CSC...Transplantation of MEC cells genetically silenced for mTOR into immunodeficient mice corroborated the results obtained with temsirolimus. Collectively, these data demonstrated that mTOR signaling is required for CSC survival, and unveiled the therapeutic potential of targeting the mTOR pathway for elimination of highly tumorigenic cancer stem-like cells in salivary gland mucoepidermoid carcinoma.
Journal
|
BMI1 (BMI1 proto-oncogene, polycomb ring finger)
|
cisplatin • paclitaxel • Torisel (temsirolimus) • buparlisib (BKM120) • sirolimus • LY294002
12ms
The Diagnostic Utility of RAS Q61R Mutation-specific Immunohistochemistry in Epithelial-Myoepithelial Carcinoma. (PubMed, Am J Surg Pathol)
IHC for RAS Q61R is highly sensitive and specific for detecting the HRAS Q61R mutation in EMC. Since significant immunopositivity was almost exclusively identified in nearly two thirds of EMCs but seldom in the histologic mimics, the IHC of RAS Q61R is a useful tool for diagnosing EMC in general pathology laboratories.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
KRAS mutation • NRAS mutation • HRAS mutation • NRAS Q61R • NRAS Q61 • HRAS Q61R
12ms
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. (PubMed, Curr Oncol)
The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. Based on the probability of the tumour harbouring an NTRK gene fusion, we also suggest a tumour-agnostic consensus for NTRK gene fusion testing and treatment. We recommend considering a TRK inhibitor in all patients with TRK fusion cancer with no other effective treatment options.
Clinical • Clinical guideline
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
|
Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)
12ms
Adenocarcinoma of the minor salivary gland with concurrent MAML2 and EWSR1 alterations. (PubMed, J Pathol Transl Med)
Fluorescence in situ hybridization revealed concurrent alterations of MAML2 and EWSR1 gene. Further investigations with a larger number of cases with similar histological and molecular features will accurately classify this tumor.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • AR (Androgen receptor) • EWSR1 (EWS RNA Binding Protein 1) • TP63 (Tumor protein 63)
12ms
Clinicopathologic and Molecular Characterization of Four Cases of Pediatric Salivary Secretory Carcinoma (SSC), One with ETV6-RET Fusion. (PubMed, Head Neck Pathol)
Similar to adult cases, this tumor is morphologically undistinguishable from those carrying the classic ETV6-NTRK3 translocation. Thus, in pediatric cases with morphology suggestive of SSC and negative ETV6-NTRK3 by RT-PCR, other possible fusions should be investigated.
Clinical • Journal
|
RET (Ret Proto-Oncogene) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • GATA3 (GATA binding protein 3) • SCGB2A2 (Secretoglobin Family 2A Member 2)
|
NTRK3 fusion • RET fusion • ETV6-NTRK3 fusion
12ms
A case of "ETV6-FISH-negative" secretory carcinoma of the parotid gland: immunohistochemical study. (PubMed, Med Mol Morphol)
However, a search using fluorescence in situ hybridization did not reveal a definite split signal for the ETV6 gene. It is presumed that confirming the diagnosis of secretory carcinoma without genetic retrieval will be accepted as a diagnostic method, and we hope that worldwide general recognition may earlier reach "gradual acceptance."
Clinical • Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • AR (Androgen receptor) • ETV6 (ETS Variant Transcription Factor 6) • VIM (Vimentin) • TP63 (Tumor protein 63) • SCGB2A2 (Secretoglobin Family 2A Member 2)
|
NTRK3 fusion • ETV6-NTRK3 fusion
1year
Expressions of microRNA-29a and microRNA-34a in pleomorphic adenomas of salivary glands. (PubMed, Gland Surg)
The conducted analyses of the expressions of miR-34a and miR-29a showed that the highest expression was observed in the salivary gland tissue adjacent to the tumor (1,052.02±367.20 and 111.93±56.97, versus 47.72±28.93 and 8.12±4.40 in the intact salivary gland tissue, respectively). There was a sufficiently high level of miR-34a and miR-29a expressions in the tissues of the tumor of pleomorphic adenomas of the salivary glands when compared with the intact salivary gland tissue.
Journal
|
MIR34A (MicroRNA 34a-5p)
1year
Sialadenoma Papilliferum of the Bronchus: An Unrecognized Bronchial Counterpart of the Salivary Gland Tumor With Frequent BRAF V600E Mutations. (PubMed, Am J Surg Pathol)
SP can develop in the central bronchus as the bronchial counterpart of the salivary gland tumor and should be considered in the differential diagnosis of endobronchial tumors. In addition, some histologic resemblance and frequent BRAF V600E mutation raise the possibility of SP and GP/MP being on the same disease spectrum.
Journal
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HRAS (Harvey rat sarcoma viral oncogene homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
BRAF V600E • BRAF V600 • PIK3CA mutation • HRAS mutation • AKT1 mutation
1year
Molecular Profiling of Salivary Oncocytic Mucoepidermoid Carcinomas Helps to Resolve Differential Diagnostic Dilemma With Low-grade Oncocytic Lesions. (PubMed, Am J Surg Pathol)
Diffuse and strong positivity for p63 and visualization of hidden mucocytes by mucicarmine staining may be misleading and does not always suffice for correct diagnosis. Our experience suggests that ancillary studies for the detection of MAML2 rearrangement may provide useful evidence in difficult cases.
Journal
|
SOX10 (SRY-Box 10) • TP63 (Tumor protein 63)
|
CRTC1-MAML2 fusion
1year
Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. (PubMed, Sci Rep)
Although nivolumab's efficacy against SGC was limited, some patients achieved long-term disease control. Further studies are warranted on ICI use for SGC.
Retrospective data • Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • CRP (C-reactive protein)
|
PD-L1 expression • MSI-H/dMMR
|
Opdivo (nivolumab)
1year
ETV6-rearranged low-grade sinonasal non-intestinal-type adenocarcinoma: a clinicopathological analysis (PubMed, Zhonghua Bing Li Xue Za Zhi)
The histomorphology is similar to other low-grade nasal sinonasal adenocarcinomas and some salivary gland tumors. IHC and FISH are useful for the diagnosis and differential diagnosis.
Clinical • Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • NR4A3 (Nuclear receptor subfamily 4 group A member 3) • NKX2-1 (NK2 Homeobox 1) • SOX10 (SRY-Box 10) • NCAM1 (Neural cell adhesion molecule 1) • VIM (Vimentin)
|
VIM expression
1year
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene (clinicaltrials.gov)
P1/2, N=82, Recruiting, Klus Pharma Inc. | Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Apr 2021
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
A166
1year
Clinical • New P1 trial • Combination therapy
|
CD4 (CD4 Molecule)
|
HER-2 positive • HER-2 amplification • HER-2 expression
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)
1year
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. (PubMed, Ann Oncol)
Overall, 12 of 19 patients (63%) with advanced SGC, treated with chemotherapy-free regimens matched to specific molecular alterations, experienced an objective response. Data from MyPathway suggest that matched targeted therapy for SGC has promising efficacy, supporting molecular profiling in treatment determination.
P2a data • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • Pan tumor
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • PTCH1 (Patched 1) • SMO (Smoothened Frizzled Class Receptor)
|
BRAF V600E • TMB-H • HER-2 amplification • HER-2 overexpression • BRAF mutation • BRAF V600 • PTCH1 mutation • BRAF amplification
|
Herceptin (trastuzumab) • Zelboraf (vemurafenib) • Tecentriq (atezolizumab) • Perjeta (pertuzumab) • Erivedge (vismodegib)
1year
Newly identified members of fibroblast growth factor receptor 1 splice variants engage in crosstalk with the AXL/AKT axis in salivary adenoid cystic carcinoma. (PubMed, Cancer Res)
Moreover, cell killing was increased by dual inhibition of AXL and FGFR1 in ACC cells. This study demonstrates that these previously undescribed FGFR1v cooperate with AXL and desensitize cells to FGFR1 inhibitor, which supports further investigation into combined FGFR1 and AXL inhibition as an effective ACC therapy.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • AXL (AXL Receptor Tyrosine Kinase) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR1 expression
1year
Molecular Pathology of Salivary Gland Neoplasms: Diagnostic, Prognostic, and Predictive Perspective. (PubMed, Adv Anat Pathol)
These genetic aberrations primarily serve as diagnostic tools in salivary gland tumor diagnosis; however, some also have promise as prognostic or predictive biomarkers. This review summarizes the latest developments in molecular pathology of salivary gland tumors with a focus on distinctive molecular characteristics.
Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • EWSR1 (EWS RNA Binding Protein 1) • ATF1 (Activating Transcription Factor 1)
1year
Secretory Carcinoma Of Salivary Gland: A Clincopathological Analysis. (PubMed, J Ayub Med Coll Abbottabad)
This study highlights the presence of specific molecular alteration in all cases, which were diagnosed based on morphology and immunohistochemistry.
Journal
|
ETV6 (ETS Variant Transcription Factor 6) • NKX2-1 (NK2 Homeobox 1) • TP63 (Tumor protein 63)
1year
Myoepithelial Carcinoma Ex Pleomorphic Adenoma of the Maxillary Sinus: A Case Report and Review of Literature. (PubMed, Head Neck Pathol)
The tumor was resected and subjected to secondary reconstruction using a revascularized free fibula flap. The myoepithelial derivation of neoplastic cells was demonstrated by immunohistochemical positivity for S-100 protein (strong and diffuse), cytokeratin 14 (strong and diffuse), and GFAP (focal).
Clinical • Review • Journal
|
KRT14 (Keratin 14) • GFAP (Glial Fibrillary Acidic Protein)
1year
SS18 Break-Apart Fluorescence In Situ Hybridization is a Practical and Effective Method for Diagnosing Microsecretory Adenocarcinoma of Salivary Glands. (PubMed, Head Neck Pathol)
Taken together, SS18 break-apart FISH was 100% sensitive and 100% specific for a diagnosis of MSA. SS18 break-apart FISH, a diagnostic tool widely available in pathology laboratories, appears to be a highly accurate method for diagnosing MSA of salivary glands. Accordingly, this new tumor type may be molecularly confirmed without needing to resort to highly specialized techniques like next-generation sequencing.
Journal
|
TP63 (Tumor protein 63)
1year
Cell adhesion molecules' altered profile in benign and malignant salivary gland tumors. The paradigm of beta4-integrin, desmoglein-2, ICAM-1 and CD44s. (PubMed, J Biol Res (Thessalon))
The different expression profile of CAMs in SGTs could possibly suggest a role on their pathogenesis, representing a model of how neoplastic cells can take advantage of normal tissue architecture and cell-extracellular matrix interactions.
Journal
|
CD44 • ICAM1 (Intercellular adhesion molecule 1)
|
CD44 expression
1year
Clinical • Enrollment closed • Combination therapy
|
AR (Androgen receptor)
|
AR positive • AR expression
|
Erleada (apalutamide) • goserelin acetate
1year
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas (clinicaltrials.gov)
P2, N=55, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 amplification • HER-2 expression
|
cisplatin • carboplatin • Kadcyla (ado-trastuzumab emtansine)
1year
Microvesicles derived from squamous cell carcinoma induce cell death, autophagy and invasion of benign myoepithelial cells. (PubMed, J Oral Pathol Med)
These findings suggest that MVs from EP modulate autophagy of Myo cells, which may, in part, explain the disappearance of these cells in in situ areas of invasive carcinoma ex-pleomorphic adenoma. Additionally, the overexpression of MMPs contributes to the development of an invasive phenotype of Myo cells, which could favor the dissolution of the basement membrane during tumorigenesis process.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
BIRC5 expression
1year
Expression Levels of SIX1, ME2 and AP2M1 in Adenoid Cystic Carcinoma and Mucoepidermoid Carcinoma. (PubMed, Oral Dis)
These results may prove that SIX1 and AP2M1 are involved in the proliferation of AdCC and MEC to cause tumor growth.
Journal
|
CCND1 (Cyclin D1)
1year
Clinical • Enrollment open • Combination therapy • CAR T-Cell Therapy • Oncolytic virus
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
TT16
1year
Extranodal B-cell marginal zone lymphoma arising in the context of a lympho-epithelial cyst of the parotid gland in a patient with clonal B-cell lymphocytosis: report of the first case. (PubMed, Minerva Stomatol)
The diagnostic evaluation of a LEC has to include the possibility of a concurrent EMZL, mainly in case of high risk biological and clinical conditions like CBL.
Clinical • Journal
|
CD5 (CD5 Molecule)
1year
Preclinical • Journal
|
BCL2L1 (BCL2-like 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • EGF (Epidermal growth factor) • CD31 (Platelet and endothelial cell adhesion molecule 1)
|
BAX expression
1year
The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma. (PubMed, Oral Oncol)
TP53-mutated recurrent and metastatic SACC was associated with shorter OS, which was significant when combined with published genomic data sets. Stratifying by TP53 status, in addition to established clinical, pathological and genomic biomarkers, may usefully inform follow-up strategy.
Journal
|
TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
TP53 mutation • PIK3CA mutation
1year
First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN. (PubMed, ESMO Open)
The Arcagen project aims to bridge the gap and improve knowledge of the molecular landscape of rare cancers by prospectively recruiting up to 1000 patients.
Journal • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
CDKN2A deletion • MDM2 amplification • RB1 deletion
|
FoundationOne® CDx • FoundationOne® Heme CDx
1year
[VIRTUAL] Primary Cutaneous Mucoepidermoid Carcinoma Clinically Mimicking Pyogenic Granuloma (ASDP 2020)
The tumor extended to the specimen margins and a recommendation for complete excision was made. This report highlights the diagnostic approach to mucoepidermoid carcinoma, a rare but relatively indolent tumor which must be distinguished from its more aggressive counterpart adenosquamous carcinoma.
Clinical
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • TP63 (Tumor protein 63)
1year
[VIRTUAL] Cutaneous Metastasis of Mucoepidermoid Carcinoma Mimicking Atypical Hidradenoma: A Potential Diagnostic Pitfall (ASDP 2020)
Previous biopsies of the scalp lesions were interpreted as nodular hidradenomas at an outside facility; however, review of the pathology of patient’s prior salivary gland mucoepidermoid carcinoma showed similar morphologic features. In the absence of an appropriate clinical history, metastatic mucoepidermoid carcinoma to the skin can be misinterpreted as nodular hidradenoma.
NCAM1 (Neural cell adhesion molecule 1)
1year
TrkB-Targeted Therapy for Mucoepidermoid Carcinoma. (PubMed, Biomedicines)
Interestingly, the spheroid forming capacity recovered, following the combination therapy, as compared to Cisplatin alone. Our studies allowed us to conclude that the TrkB inhibition, efficiently impaired MEC cell migration, invasion and survival in vitro, however, the decrease in CSC number, following the combined treatment of ANA-12 and Cisplatin, was less than that seen with Cisplatin alone; this represents a limiting factor.
Journal
|
NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
|
cisplatin
1year
Adenoid cystic carcinoma with dedifferentiation/expansion of the luminal cell component and preserved biphasic morphology - Early high-grade transformation. (PubMed, Ann Diagn Pathol)
We present two patients (29 and 67 years) with histomorphologic and immunohistochemical evidence of early high-grade transformation of adenoid cystic carcinoma in the nasal cavity and floor of mouth, respectively. The component of early high-grade transformation was characterized by 1) selective expansion of the luminal (CK7+, c-kit+, p63-) cell component with severe cytologic atypia and significantly increased Ki-67 proliferation index, and 2) retained albeit attenuated abluminal (CK7-, c-kit-, p63+) cells, surrounding nests of high-grade luminal cells.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • TP63 (Tumor protein 63)
1year
Tumor microenvironment in salivary gland carcinomas: Consequences for new therapeutic concepts (PubMed, HNO)
LAG3 is particularly detectable in aggressive entities and advanced tumors. Hence, LAG3 inhibition poses a potential targeted therapy for advanced and metastatic SGCs.
Review • Journal • PD(L)-1 Biomarker
|
LAG3 (Lymphocyte Activating 3)
|
LAG3 expression • TILs
1year
The significance of tyrosine kinase receptor B and brain-derived neurotrophic factor expression in salivary duct carcinoma. (PubMed, Ann Diagn Pathol)
There were no significant differences or correlations in mRNA expression. Our results suggest that TrkB may be involved in SDC tumor growth.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
1year
Expanding the Molecular Spectrum of Secretory Carcinoma of Salivary Glands With a Novel VIM-RET Fusion. (PubMed, Am J Surg Pathol)
A novel finding in our study was the discovery of a VIM-RET fusion in 1 patient with SC of the parotid gland who could possibly benefit from RET-targeted therapy. In addition, 1 recurrent high-grade case was shown to harbor 2 different fusions, namely, ETV6-NTRK3 and MYB-SMR3B. The expanded molecular spectrum provides a novel insight into SC oncogenesis and carries important implications for molecular diagnostics, as this is the first SC-associated translocation with a non-ETV6 5' fusion partner. This finding further expands the definition of SC while carrying implications for selecting the appropriate targeted therapy.
Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK3 fusion • RET fusion • ETV6-NTRK3 fusion • MET fusion
1year
ALK alterations in salivary gland carcinomas. (PubMed, Virchows Arch)
ALK rearrangements are a rare entity in salivary gland carcinomas. We identified a potentially targetable novel ALK fusion in an intraductal carcinoma of minor salivary glands.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53)
|
TP53 mutation • HER-2 amplification • BRAF mutation • ALK positive • ALK rearrangement • ALK fusion
1year
VISTA: Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (clinicaltrials.gov)
P1, N=39, Not yet recruiting, Baylor College of Medicine | Trial completion date: Sep 2038 --> Dec 2038 | Trial primary completion date: Sep 2024 --> Dec 2024
Clinical • Trial completion date • Trial primary completion date • Combination therapy • CAR T-Cell Therapy • Oncolytic virus
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
TT16
1year
Primary De novo ductal adenocarcinoma of the lacrimal gland. (PubMed, Ann Diagn Pathol)
Authors have expressed the need of clinical correlation; thorough tissue sampling and extensive immunohistochemical work up in identification of de novo PDA's and their molecular subtypes. A multi-institutional study might help in formulating the diagnostic criteria, identification of actionable targets, and thus study the role of targeted therapy in this rare and aggressive tumor which may result in better patient outcomes.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CCND1 (Cyclin D1) • NKX2-1 (NK2 Homeobox 1)
|
HER-2 expression • CCND1 expression
1year
Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease. (PubMed, Front Oncol)
Secretory carcinoma, previously known as mammary analog secretory carcinoma, is distinguished by an ETV6-NTRK3 fusion that can both help differentiate it from its morphologically similar acinar cell carcinoma and make it susceptible to Trk inhibitors. In the present article, we discuss the molecular abnormalities, their impact on tumor biology, and therapeutic opportunities for the most common SGC subtypes and review published and ongoing clinical trials and future perspectives for this rare disease.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • AR (Androgen receptor) • NOTCH1 (Notch 1) • ETV6 (ETS Variant Transcription Factor 6)
|
HER-2 overexpression • NTRK3 fusion • ETV6-NTRK3 fusion • NOTCH1 mutation • AR expression • NOTCH1 expression
1year
Expression of NR4A3/NOR-1 in acinic cell carcinoma of the salivary gland (PubMed, Zhonghua Bing Li Xue Za Zhi)
Furthermore, NR4A3/NOR-1 were only positive for AciCC arising from salivary glands but not pancreas(0/2)(P=0.018). NR4A3/NOR-1 is a special and sensitive biomarker for AciCC of salivary glands; combined NR4A3/NOR-1 and DOG1 can be an ideal diagnostic immunohistochemical panel for AciCC.
Journal
|
NR4A3 (Nuclear receptor subfamily 4 group A member 3)
1year
Clinical • Enrollment closed
|
AR (Androgen receptor)
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
1year
[VIRTUAL] Evaluation of Three RNA Quantification Methods for NextGeneration Sequencing of Formalin-Fixed, Paraffin-Embedded Tumor Samples (AMP 2020)
For OFA, the vendor recommends using GUSB-RT-PCR to determine amplifiable RNA quantity. Based on our results, GUSB-RT-PCR is able to provide a wide range of RNA measurements across various samples sizes; but it comes with associated labor and reagents costs. Considering wider range of RNA measurements, Quantus is an acceptable alternative to GUSB assay.
Next-generation sequencing
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
MET exon 14 mutation • ALK fusion
1year
[VIRTUAL] CANTRK: A Canadian Multi-Centre NTRK Gene Fusion Testing Validation in Solid Tumors Project (AMP 2020)
Availability of NTRK+ samples for validation of NTRK tests is challenging. CANTRK provides a framework for biomarker assay validation projects involving rare cancers. A multi-centre collaboration is instrumental in this setting to overcome the challenges faced by individual laboratories to source sufficient positive samples for independent validation and clinical implementation.
Clinical
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK1 fusion • NTRK2 fusion • NTRK fusion • NTRK positive
|
VENTANA pan-TRK (EPR17341) Assay
1year
[VIRTUAL] Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion Testing in Clinical Trials of Larotrectinib (AMP 2020)
These results demonstrate that NTRK fusions occur with many partners, supporting the need for validated and reliable testing methodologies. RNA-based NGS was the most commonly used testing method used in identifying NTRK fusions in the 3 clinical trials.
Clinical
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ETV6 (ETS Variant Transcription Factor 6) • TPM3 (Tropomyosin 3) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • NTRK fusion
|
Vitrakvi (larotrectinib)
1year
Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma. (PubMed, Head Neck)
The data from this retrospective study highlighting the uniform microsatellite stability alongside the low prevalence of CPS positivity suggests that only a minority of SGC patients may benefit from ICI therapy alone. The high rates of EGFR expression in SGC may be a target to augment immune checkpoint therapy response.
Journal • PD(L)-1 Biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • EGFR expression
1year
Lymph node metastasis of parotid gland high-grade adenoid-cystic carcinoma. (PubMed, Cesk Patol)
Interestingly, there was strong CD117 expression in the high-grade ACC, whereas the conventional part was fully negative. To the best of our knowledge, the high-grade ACC of the parotid gland was reported only in 10 cases in the medical literature.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
KIT expression
1year
[VIRTUAL] A case of pleomorphic adenoma of the parotid gland in a patient of nodular sclerosis classical Hodgkin lymphoma (ECP 2020)
These findings were consistent with Nodular sclerosis classical Hodgkin lymphoma. Conclusion We report a rare case of Pleomorphic adenoma in a patient of Nodular sclerosis classical Hodgkin lymphoma; Large scale surveillance studies are suggested to truly establish and quantify the risk for development of Pleomorphic adenoma in patients suffering from Nodular sclerosis classical Hodgkin Lymphoma.
Clinical
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • FUT4 (Fucosyltransferase 4)
1year
[VIRTUAL] Use of GFAP, B-catenin and DOG-1 in the differential diagnosis of benign biphasic basaloid salivary gland tumours (ECP 2020)
Conclusion In our experience this IHC panel is useful in this differential diagnosis where even though both entities are benign, PA has a higher recurrence and malignancy rate, so a correct diagnosis has important prognostic implications. Besides, although some literature reports comment on the expression of these markers in different salivary gland tumors, to the best of our knowledge, there are no reports comparing its expression in PA and BCA.
GFAP (Glial Fibrillary Acidic Protein)
1year
[VIRTUAL] A rare case of metastasis of breast carcinoma to buccal mucosa mimicking acinic cell carcinoma (ECP 2020)
Most of the reported cases have an interval of 2 years. The combination of medical history and a panel of immuno-histochemical stains and interest in both breast and salivary gland pathology are key to achieve the correct diagnosis as shown in our case.
Clinical
|
PGR (Progesterone receptor)
1year
[VIRTUAL] Aggressive neoplasia in the maxillary sinus in women in the eighth decade of life - case report and literature review (ECP 2020)
Conclusion redictors of survival in SNACC include age, comorbidity status, grade, and stage. Surgery is associated with improved survival and remains the mainstay of therapy, whereas the roles of radiation therapy and chemotherapy require future investigation, where patholgy has the main perspective.
Clinical
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • TP63 (Tumor protein 63)
1year
[VIRTUAL] Carcinoma showing thymus-like element (castle) of the submandibular gland: report of an extremely rare case (ECP 2020)
The origin of salivary CASTLE remans unknown. We discuss the differential diagnosis of salivary CASTLE from myoepithelial carcinoma, lymphoepithelial carcinoma or basaloid carcinoma of the salivary glands
Clinical
|
EGFR (Epidermal growth factor receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD5 (CD5 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • TP63 (Tumor protein 63)
1year
[VIRTUAL] Basal cell adenoma of parotid: a cytological diagnosis confirmed by histology (ECP 2020)
Conclusion Basal cell adenomas of the salivary glands have a low recurrence rate and they rarely demonstrate malignant transformation. FNA is usually followed by surgery, in order to assure the complete resection and to minimize the chances for recurrence.
VIM (Vimentin)
1year
[VIRTUAL] Polymorphous adenocarcinoma of the breast: a rare salivary gland-like tumour (ECP 2020)
Conclusion Herein we describe a case of Polymorphous adenocarcinoma of the breast, a rare tumor characterized by diverse morphology, negativity for ER, PR and HER2, absence of a biphasic cellular pattern and diffuse positivity for BCL2. This diagnosis should be suspected in carcinomas with apparent discrepancy of a triple-negative immunoprofile and a well-differentiated histology, and without the typical dual cell population of other salivary gland-like neoplasms of the breast.
IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
1year
[VIRTUAL] HRAS mutation is a surrogate diagnostic marker in challenging cases of epithelial-myoepithelial carcinoma (ECP 2020)
We demonstrated that HRAS mutations are present in these variant EMCs. Thus assessment of HRAS status is useful in salivary gland neoplasms that do not entirely fulfil clear diagnostic criteria for EMC and cannot otherwise be classified as other entities.
Clinical
|
HRAS (Harvey rat sarcoma viral oncogene homolog)
|
HRAS mutation • NRAS Q61R • HRAS Q61R
1year
[VIRTUAL] The diagnostic utility of RAS Q61R mutation-specific immunohistochemistry in epithelial-myoepithelial carcinoma (ECP 2020)
Further studies will be needed to clarify the molecular mechanisms underlying the differences in the immunoexpression between the ductal and myoepithelial cells in HRAS Q61R mutation-positive EMCs. Since significant immunopositivity was exclusively identified in more than two-third of EMCs but not in the histologic mimics, the immunohistochemistry of RAS Q61R is a useful tool for diagnosing EMC in general pathology laboratories.
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
KRAS mutation • NRAS mutation • HRAS mutation • NRAS Q61R • NRAS Q61 • HRAS Q61R
1year
[VIRTUAL] P62/sequestosome1(sqstm1) and GATA3 expression in salivary duct carcinoma: in comparison with pleomorphic adenoma (ECP 2020)
As SQSTM1 is also a marker for apocrine differentiation, it is better that SDC is called “apocrine carcinoma of the salivary gland”. Although GATA3 has been also reported the consequential positivity in secretory carcinoma of the salivary gland, it could be one of the sensitive diagnostic markers for SDC, adding to AR, GADFP-15 and SQSTM1
SQSTM1 (Sequestosome 1) • GATA3 (GATA binding protein 3)
1year
[VIRTUAL] Secretory carcinoma of the parotid gland a new entity: a case series (ECP 2020)
It is the only salivary gland tumor related to ETV6-NTRK3 gene fusion. Nowadays, its presence is useful for diagnosis and specific treatment.
Clinical
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK3 fusion • ETV6-NTRK3 fusion
1year
[VIRTUAL] Carcinoma showing thymus-like element (castle) of the submandibular gland: report of an extremely rare case (ECP 2020)
The origin of salivary CASTLE remans unknown. We discuss the differential diagnosis of salivary CASTLE from myoepithelial carcinoma, lymphoepithelial carcinoma or basaloid carcinoma of the salivary glands
Clinical
|
EGFR (Epidermal growth factor receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD5 (CD5 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • TP63 (Tumor protein 63)
1year
[VIRTUAL] A rare case of metastasis of breast carcinoma to buccal mucosa mimicking acinic cell carcinoma (ECP 2020)
Most of the reported cases have an interval of 2 years. The combination of medical history and a panel of immuno-histochemical stains and interest in both breast and salivary gland pathology are key to achieve the correct diagnosis as shown in our case.
Clinical
|
PGR (Progesterone receptor)
1year
[VIRTUAL] Aggressive neoplasia in the maxillary sinus in women in the eighth decade of life - case report and literature review (ECP 2020)
Conclusion redictors of survival in SNACC include age, comorbidity status, grade, and stage. Surgery is associated with improved survival and remains the mainstay of therapy, whereas the roles of radiation therapy and chemotherapy require future investigation, where patholgy has the main perspective.
Clinical
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • TP63 (Tumor protein 63)
1year
[VIRTUAL] A case of pleomorphic adenoma of the parotid gland in a patient of nodular sclerosis classical Hodgkin lymphoma (ECP 2020)
These findings were consistent with Nodular sclerosis classical Hodgkin lymphoma. Conclusion We report a rare case of Pleomorphic adenoma in a patient of Nodular sclerosis classical Hodgkin lymphoma; Large scale surveillance studies are suggested to truly establish and quantify the risk for development of Pleomorphic adenoma in patients suffering from Nodular sclerosis classical Hodgkin Lymphoma.
Clinical
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • FUT4 (Fucosyltransferase 4)
1year
[VIRTUAL] Use of GFAP, B-catenin and DOG-1 in the differential diagnosis of benign biphasic basaloid salivary gland tumours (ECP 2020)
Conclusion In our experience this IHC panel is useful in this differential diagnosis where even though both entities are benign, PA has a higher recurrence and malignancy rate, so a correct diagnosis has important prognostic implications. Besides, although some literature reports comment on the expression of these markers in different salivary gland tumors, to the best of our knowledge, there are no reports comparing its expression in PA and BCA.
GFAP (Glial Fibrillary Acidic Protein)
1year
[VIRTUAL] Polymorphous adenocarcinoma of the breast: a rare salivary gland-like tumour (ECP 2020)
Conclusion Herein we describe a case of Polymorphous adenocarcinoma of the breast, a rare tumor characterized by diverse morphology, negativity for ER, PR and HER2, absence of a biphasic cellular pattern and diffuse positivity for BCL2. This diagnosis should be suspected in carcinomas with apparent discrepancy of a triple-negative immunoprofile and a well-differentiated histology, and without the typical dual cell population of other salivary gland-like neoplasms of the breast.
IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
1year
[VIRTUAL] Basal cell adenoma of parotid: a cytological diagnosis confirmed by histology (ECP 2020)
Conclusion Basal cell adenomas of the salivary glands have a low recurrence rate and they rarely demonstrate malignant transformation. FNA is usually followed by surgery, in order to assure the complete resection and to minimize the chances for recurrence.
VIM (Vimentin)
1year
[VIRTUAL] P62/sequestosome1(sqstm1) and GATA3 expression in salivary duct carcinoma: in comparison with pleomorphic adenoma (ECP 2020)
As SQSTM1 is also a marker for apocrine differentiation, it is better that SDC is called “apocrine carcinoma of the salivary gland”. Although GATA3 has been also reported the consequential positivity in secretory carcinoma of the salivary gland, it could be one of the sensitive diagnostic markers for SDC, adding to AR, GADFP-15 and SQSTM1
SQSTM1 (Sequestosome 1) • GATA3 (GATA binding protein 3)
1year
[VIRTUAL] HRAS mutation is a surrogate diagnostic marker in challenging cases of epithelial-myoepithelial carcinoma (ECP 2020)
We demonstrated that HRAS mutations are present in these variant EMCs. Thus assessment of HRAS status is useful in salivary gland neoplasms that do not entirely fulfil clear diagnostic criteria for EMC and cannot otherwise be classified as other entities.
Clinical
|
HRAS (Harvey rat sarcoma viral oncogene homolog)
|
HRAS mutation • NRAS Q61R • HRAS Q61R
1year
[VIRTUAL] The diagnostic utility of RAS Q61R mutation-specific immunohistochemistry in epithelial-myoepithelial carcinoma (ECP 2020)
Further studies will be needed to clarify the molecular mechanisms underlying the differences in the immunoexpression between the ductal and myoepithelial cells in HRAS Q61R mutation-positive EMCs. Since significant immunopositivity was exclusively identified in more than two-third of EMCs but not in the histologic mimics, the immunohistochemistry of RAS Q61R is a useful tool for diagnosing EMC in general pathology laboratories.
KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
KRAS mutation • NRAS mutation • HRAS mutation • NRAS Q61R • NRAS Q61 • HRAS Q61R
1year
[VIRTUAL] Secretory carcinoma of the parotid gland a new entity: a case series (ECP 2020)
It is the only salivary gland tumor related to ETV6-NTRK3 gene fusion. Nowadays, its presence is useful for diagnosis and specific treatment.
Clinical
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK3 fusion • ETV6-NTRK3 fusion
1year
[VIRTUAL] Aggressive neoplasia in the maxillary sinus in women in the eighth decade of life - case report and literature review (ECP 2020)
Conclusion redictors of survival in SNACC include age, comorbidity status, grade, and stage. Surgery is associated with improved survival and remains the mainstay of therapy, whereas the roles of radiation therapy and chemotherapy require future investigation, where patholgy has the main perspective.
Clinical
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • TP63 (Tumor protein 63)
1year
[VIRTUAL] A case of pleomorphic adenoma of the parotid gland in a patient of nodular sclerosis classical Hodgkin lymphoma (ECP 2020)
These findings were consistent with Nodular sclerosis classical Hodgkin lymphoma. Conclusion We report a rare case of Pleomorphic adenoma in a patient of Nodular sclerosis classical Hodgkin lymphoma; Large scale surveillance studies are suggested to truly establish and quantify the risk for development of Pleomorphic adenoma in patients suffering from Nodular sclerosis classical Hodgkin Lymphoma.
Clinical
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • FUT4 (Fucosyltransferase 4)
1year
[VIRTUAL] Carcinoma showing thymus-like element (castle) of the submandibular gland: report of an extremely rare case (ECP 2020)
The origin of salivary CASTLE remans unknown. We discuss the differential diagnosis of salivary CASTLE from myoepithelial carcinoma, lymphoepithelial carcinoma or basaloid carcinoma of the salivary glands
Clinical
|
EGFR (Epidermal growth factor receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD5 (CD5 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • TP63 (Tumor protein 63)
1year
[VIRTUAL] A rare case of metastasis of breast carcinoma to buccal mucosa mimicking acinic cell carcinoma (ECP 2020)
Most of the reported cases have an interval of 2 years. The combination of medical history and a panel of immuno-histochemical stains and interest in both breast and salivary gland pathology are key to achieve the correct diagnosis as shown in our case.
Clinical
|
PGR (Progesterone receptor)
1year
[VIRTUAL] Use of GFAP, B-catenin and DOG-1 in the differential diagnosis of benign biphasic basaloid salivary gland tumours (ECP 2020)
Conclusion In our experience this IHC panel is useful in this differential diagnosis where even though both entities are benign, PA has a higher recurrence and malignancy rate, so a correct diagnosis has important prognostic implications. Besides, although some literature reports comment on the expression of these markers in different salivary gland tumors, to the best of our knowledge, there are no reports comparing its expression in PA and BCA.
GFAP (Glial Fibrillary Acidic Protein)